

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




AH1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>C07D 401/14, 401/06, 401/04, 405/14, 417/06, 211/22, 409/14, 211/70, A61K 31/445</b>		(11) International Publication Number: <b>WO 97/30990</b>
A1		(43) International Publication Date: 28 August 1997 (28.08.97)
(21) International Application Number: PCT/US97/02239 (22) International Filing Date: 27 January 1997 (27.01.97) (30) Priority Data: 08/604,202      21 February 1996 (21.02.96)      US 08/771,544      23 December 1996 (23.12.96)      US (71) Applicant: HOECHST MARION ROUSSEL, INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventors: MAYNARD, George, D.; Apartment C, 9214 Hunters Creek Drive, Cincinnati, OH 45242 (US). KANE, John, M.; 6813 Dearwester Drive, Cincinnati, OH 45236 (US). BRATTON, Larry, D.; 10453 Nelson Street, West- minister, CO 80021 (US). KUDLACZ, Elizabeth, M.; 10856 Lake Thames, Cincinnati, OH 45242 (US). (74) Agent: STEMERICK, David, M.; Hoechst Marion Roussel, Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincin- nati, OH 45215-6300 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NOVEL SUBSTITUTED N-METHYL-N-(4-(PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES



(57) Abstract

The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of formula (I), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

10 NOVEL SUBSTITUTED N-METHYL-N-(4-(PIPERIDIN-1-YL)-2-  
(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC  
DISEASES

15

The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives (herein referred to as a compound or compounds  
20 of formula (1)) and their use as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of asthma; bronchitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; allergic rhinitis,  
25 including seasonal rhinitis and sinusitis; allergies; and emesis.

The compounds of the present invention are useful in their pharmacological activities, such as histamine  
30 receptor antagonism and tachykinin receptor antagonism. Antagonism of histamine responses can be elicited through blocking of histamine receptors. Antagonism of tachykinin

35

responses can be elicited through blocking of tachykinin  
receptors. One object of the present invention is to  
5 provide new and useful antagonists of histamine. A  
further object of the present invention is to provide new  
and useful antagonists of tachykinins. A particular  
object of the present invention are those compounds that  
exhibit both H<sub>1</sub> and NK<sub>1</sub> receptor antagonism.

10

15

20


25

30

35

SUMMARY OF THE INVENTION


5 The present invention provides novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula:



15 wherein

R' is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

20 R'' is hydrogen or a radical chosen from the group consisting of




wherein

30 R<sub>20</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, and -CF<sub>3</sub>;

35

Ar<sub>1</sub> is a radical chosen from the group consisting of




R<sub>1</sub> is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen, hydroxy, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

R<sub>2</sub> is from 1 to 2 substituents each independently chosen from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

X<sub>1</sub> and X<sub>2</sub> are as defined in one of parts A), B), or C):

A)  $X_1$  is hydrogen;

$X_2$  is a radical chosen from the group consisting of



wherein


$p$  is 1 or 2;

$R_3$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $-CF_3$ ,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy;

$R_4$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $-CF_3$ ,  $C_1-C_6$  alkyl, and  $C_1-C_6$  alkoxy,

$R_5$  is hydrogen or hydroxy;

$Ar_2$  is a radical chosen from the group consisting of



$R_6$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $-CF_3$ ,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, and  $-CO_2R_9$  wherein  $R_9$  is chosen from the group consisting of hydrogen and  $C_1-C_4$  alkyl;

$R_7$  is from 1 to 2 substituents each independently chosen from the group consisting of hydrogen, halogen,  $C_1-C_6$  alkyl, and  $C_1-C_6$  alkoxy;

$R_8$  is chosen from the group consisting of hydrogen,  $-CH_3$ , and  $-CH_2OH$ ;

$R_{10}$  is chosen from the group consisting of hydrogen,  $C_1-C_4$  alkyl, and benzyl;

$Z$  is chosen from the group consisting of hydrogen,  $C_1-C_6$  alkyl,  $-(CH_2)_w-O-(CH_2)_t-Y$ ,  $-(CH_2)_fA$ ,  $-(CH_2)_uCO_2R_{11}$ ,



-7-

5  $-(CH_2)_u C(O)NR_{12}R_{13}$ ,  $-(CH_2)_g C(O)(CH_2)_h CH_3$ ,  $-(CH_2)_w -O-Ar_3$ ,  
 $-CH_2CH_2OCF_3$ ,  $-CH_2CF_3$ ,  $-CH_2CH_2CH_2CF_3$ ,  $-(CH_2)_2CH=CH_2$ ,  
 $-CH_2CH=CH_2$ ,  $-CH_2CH=CHCH_3$ ,  $-CH_2CH=CHCH_2CH_3$ ,  
 $-CH_2CH=C(CH_3)_2$ , and  $-CH_2OCH_2CH_2Si(CH_3)_3$

wherein

10 w is an integer from 2 to 5;

t is an integer from 1 to 3;

f is 2 or 3;

15 u is an integer from 1 to 4;

g is an integer from 1 to 3;

h is an integer from 0 to 3;

20 w is an integer from 2 to 4;

Y is chosen from the group consisting of hydrogen,  
25  $-CF_3$ ,  $-CH=CH_2$ ,  $-CH=C(CH_3)_2$ , and  $-CO_2R_{14}$  wherein  $R_{14}$   
is chosen from the group consisting of hydrogen and  
 $C_1-C_4$  alkyl;


30 A is chosen from the group consisting of  $-NR_{15}R_{16}$ ,  
acetylamino, and morpholino wherein  $R_{15}$  is chosen  
from the group consisting of hydrogen and  $C_1-C_4$   
alkyl and  $R_{16}$  is  $C_1-C_4$  alkyl;

$R_{11}$  is chosen from the group consisting of hydrogen  
and  $C_1-C_4$  alkyl;

35  $R_{12}$  is chosen from the group consisting of  
hydrogen,  $C_1-C_4$  alkyl, and benzyl;

$R_{13}$  is chosen from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl;

5  $Ar_3$  is a radical chosen from the group consisting of



wherein


$v$  is an integer from 1 to 3;

15

$R_{17}$  is chosen from the group consisting of hydrogen and  $-CO_2R_{18}$  wherein  $R_{18}$  is chosen from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl;

20 B)  $X_1$  is hydroxy;

$X_2$  is a radical chosen from the group consisting of




30

wherein  $p$ ,  $R_3$ ,  $Z$ , and  $Ar_2$  are as previously defined;

35

C)  $X_2$  is a radical of the formula;



wherein  $R_3$  and  $R_4$  are as previously defined; and

$X_1$  and  $Z_1$  taken together form a second bond between the carbon atoms bearing  $X_1$  and  $Z_1$ ;

15 and stereoisomers and pharmaceutically acceptable salt thereof.

As is appreciated by one of ordinary skill in the art  
20 the compounds of the formula (1) may exist as stereoisomers N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide. Specifically, it is recognized that the the present N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides exist as stereoisomers at the 2-  
25 position of the butyl, that is, at the point of attachment of the aryl substituent. Any reference in this application to one of the compounds of the formula (1) is meant to encompass either specific stereoisomers or a mixture of stereoisomers.


30 The specific stereoisomers can be prepared by stereospecific synthesis using enantiomerically pure or enantiomerically enriched starting materials. The specific stereoisomers of either starting materials or  
35 products can be resolved and recovered by techniques known in the art, such as chromatography on chiral stationary phases, enzymatic resolution, or fractional recrystallization of addition salts formed by reagents

- us d for that purpose. Useful methods of resolving and recovering specific stereoisomers are known in the art and described in Stereochemistry of Organic Compounds, E. L. Eliel and S. H. Wilen, Wiley (1994) and Enantiomers, Racemates, and Resolutions, J. Jacques, A. Collet, and S. H. Wilen, Wiley (1981).

As used in this application:

10

- a) the term "halogen" refers to a fluorine atom, chlorine atom, bromine atom, or iodine atom;
- b) the term "C<sub>1</sub>-C<sub>6</sub> alkyl" refers to a branched or straight  
15 chained alkyl radical containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, etc;
- 20 c) the term "C<sub>1</sub>-C<sub>6</sub> alkoxy" refers to a straight or branched alkoxy group containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, pentoxy, hexoxy, cyclopentoxy, cyclohexoxy, etc;
- 25 d) the designations -C(O)- or -(O)C- refer to a carbonyl group of the formula:



30


- e) the designation " ~~~~ " refers to a bond for which the stereochemistry is not designated;
- 35 f) as used in the examples and preparations, the following terms have the meanings indicated: "kg" refers to kilograms, "g" refers to grams, "mg" refers to milligrams, "µg" refers to micrograms, "mol" refers to moles, "mmol" refers to

-11-

millimol s, "nmole" refers to nanomoles, "L" refers to liters, "mL" or "ml" refers to milliliters, "μL" refers to microliters, "°C" refers to degrees Celsius, "R<sub>f</sub>" refers to retention factor, "mp" refers to melting point, "dec" refers to decomposition, "bp" refers to boiling point, "mm of Hg" refers to pressure in millimeters of mercury, "cm" refers to centimeters, "nm" refers to nanometers, "[α]<sub>D</sub><sup>20</sup>" refers to specific rotation of the D line of sodium at 20° C obtained in a 1 decimeter cell, "c" refers to concentration in g/mL, "THF" refers to tetrahydrofuran, "DMF" refers to dimethylformamide, "brine" refers to a saturated aqueous sodium chloride solution, "M" refers to molar, "mM" refers to millimolar, "μM" refers to micromolar, "nM" refers to nanomolar, "psi" refers to pounds per square inch, "TLC" refers to thin layer chromatography, "HPLC" refers to high performance liquid chromatography, "HRMS" refers to high resolution mass spectrum, "μCi" refers to microcuries, "i.p." refers to intraperitoneally, "i.v." refers to intravenously, and "DPM" refers to disintegrations per minute;

g) the designation

25




refers to a phenyl or a substituted phenyl and it is understood that the radical is attached at the 1-position and the substituent or substituents represented by R can be attached in any of the 2, 3, 4, 5, or 6 positions;

35

h) the designation


5



10 refers to a pyridine, substituted pyridine, pyridyl or substituted pyridyl and it is understood that the radical can be attached at either the 2-position, the 3-position, or the 4-position, it is further understood that when the radical is attached at the 2-position the substituent or substituents represented by R can be attached in any of the 3, 4, 5, or 6 positions, that when the radical is attached at the 3-position the substituent or substituents represented by R can be attached in any of the 2, 4, 5, or 6 positions, and that when the radical is attached at the 4-position the substituent or substituents represented by R can be attached in any of the 2, 3, 5, or 6 positions;

i) the designation

25




refers to a thienyl or thiophene and it is understood that the radical is attached at the 2 or 3-positions;

30

j) the designation

35



refers to a naphthyl or substituted naphthyl and it is understood that the radical can be attached at either the 1-

position or the 2-position, it is further understood that when the radical is attached at the 1-position the substituent or substituents represented by R can be attached in any of the 2, 3, 4, 5, 6, 7, or 8 positions and that when the radical is attached at the 2-position the substituent or substituents represented by R can be attached in any of the 1, 3, 4, 5, 6, 7, or 8 positions;


10 k) the term "enantiomeric excess" or "ee" refers to the percent by which one enantiomer, E1, is in excess in a mixture of the two enantiomers, E1 plus E2, such that

$$\{(E1 - E2) \div (E1 + E2)\} \times 100\% = ee,$$

15 with the designation "(+)-" refers to the plus enantiomer, "(-)-" refers to the minus enantiomer;


1) the term "C<sub>1</sub>-C<sub>4</sub> alkyl" refers to a saturated straight or  
20 branched chain alkyl group containing from 1-4 carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, and t-butyl;

m) the designations -CO<sub>2</sub>R and -C(O)OR refer to a group of  
25 the formula:




30

n) the designation -C(O)NRR refers to a group of the formula:



35

o) the designation



5

refers to a furyl or furan and it is understood that the radical is attached at either the 2- or 3-position;

10 p) the term "pharmaceutically acceptable salts thereof refers to either an acid addition salt or a basic addition salt.

15 The expression "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salt of the base compounds represented by formula (1) or any of its intermediates. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric, and phosphoric  
20 acid and acid metal salts such as sodium monohydrogen orthophosphate, and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di-, and tricarboxylic acids. Illustrative of such acids are for example, acetic, glycolic, lactic,  
25 pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid, and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic  
30 acid. Such salts can exist in either a hydrated or substantially anhydrous form. In general, the acid addition salts of these compounds are soluble in water and various hydrophilic organic solvents, and which in comparison to their free base forms, generally demonstrate higher melting  
35 points.

The expression "pharmaceutically acceptable basic addition salts" is intended to apply to any non-toxic




organic or inorganic basic addition salts of the compounds represented by formula (1) or any of its intermediates. Illustrative bases which form suitable salts include alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium, magnesium, or barium hydroxides; ammonia, and aliphatic, alicyclic, or aromatic organic amines such as methylamine, dimethylamine, trimethylamine, and picoline.

10

Preferred embodiments of formula (1) are given below:

1) Compounds wherein  $X_1$  is hydrogen are preferred;


15 2) Compounds wherein  $X_2$  is a radical of the formula



are preferred;


25

3) Compounds wherein  $X_2$  is a radical of the formula




35 wherein  $p$  is 1 and  $Ar_2$  is 4-fluorophenyl, pyrid-2-yl, fur-2-yl, or fur-3-yl are more preferred;

- 4) Compounds where in  $X_2$  is a radical of the formula



10 are preferred; and

- 5) Compounds wherein  $X_2$  is a radical of the formula



20 wherein  $Z$  is  $-(CH_2)_w-O-(CH_2)_t-Y$  wherein  $w$  is 2 are more preferred, with compounds wherein  $Z$  is 2-ethoxyethyl being most preferred.

Examples of compounds encompassed by the present invention include the following. It is understood that the 25 examples encompass both the (+)-isomer and the (-)-isomer of the compound and mixtures thereof. This list is meant to be representative only and is not intended to limit the scope of the invention in any way:

30 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

35 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

- N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 5 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 10 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 15 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 20 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 25 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- 30 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

5 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

10

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidin-1-yl)-2-phenylbutyl)benzamide;

15 N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

20 N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

25

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

30 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

35 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

15 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

20 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

25 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

30 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

35 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

5

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

10 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;

15 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

20 N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

25

N-Methyl-N-(4-(4-(1-(3-(4-fluorophenoxy)propyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

30 N-Methyl-N-(4-(4-(1-(3-(4-fluorophenoxy)propyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

35 N-Methyl-N-(4-(4-(1-(3-(4-fluorophenoxy)propyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

- 5 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

- 10 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

- 15 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

- 20 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;

- 25 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

- 30 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

- 35 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

- 40 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;

- 45 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;
- 5
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 10
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-
- 15
- trimethoxybenzamide;
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;
- 20
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-
- 25
- carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-
- 30
- 3,4,5-trimethoxybenzamide;
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;
- 35
- N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;



N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

10

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

15 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

20 N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

25 N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

30 N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

35

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

15

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

20

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

25

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

30

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

35

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

- N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;  
5
- N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- 10 N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;  
15
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;  
20
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;
- 25 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;  
30
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;  
35
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

- 5 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 10 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;
- 15 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 20 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;
- 25 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- 30 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;
- 35 N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-  
5 3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;  
15

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;  
20

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;

25 N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;  
30

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;  
35

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

15

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

20

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

25

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;

30

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

35

N-Methyl-N-(4-(4-(1-(2-oxobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-oxobutyl)-1H-benzimidazol-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(2-oxobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

10 N-Methyl-N-(4-(4-(1-(2-oxobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-methyl-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

15

N-Methyl-N-(4-(4-(1-methyl-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

20 N-Methyl-N-(4-(4-(1-methyl-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(3-(4-carboxyphenyl)propyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

25

N-Methyl-N-(4-(4-(1-(3-(4-carboxyphenyl)propyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

30

N-Methyl-N-(4-(4-(1-(3-(4-carboxyphenyl)propyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide

35 N-Methyl-N-(4-(4-(1-(2-oxopropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-oxopropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(2-oxopropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

10 N-Methyl-N-(4-(4-(1-(2-oxopropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(5-methylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

15

N-Methyl-N-(4-(4-(1-(5-methylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

20

N-Methyl-N-(4-(4-(1-(5-methylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

25

N-Methyl-N-(4-(4-(1-(5-methylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

30 N-Methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

N-Methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

35



N-Methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

15

N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

20 N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

25

N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

30

N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

35 N-Methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

5

N-Methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(3-ethoxycarbonylpropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

15

N-Methyl-N-(4-(4-(1-(3-ethoxycarbonylpropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

20

N-Methyl-N-(4-(4-(1-(3-ethoxycarbonylpropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

25

N-Methyl-N-(4-(4-(1-(2-(morpholin-4-yl)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

30 N-Methyl-N-(4-(4-benzhydrylidene-piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-benzhydrylidene-piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

35

N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide

N-Methyl-N-(4-(4-(1-(fur-3-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-ethyl-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-propyl-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

15 N-Methyl-N-(4-(4-(1-butyl-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(2-carboxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

20

N-Methyl-N-(4-(4-(1-(thien-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-(dimethylamino)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

25

N-Methyl-N-(4-(4-(1-(2-phenoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

30

N-Methyl-N-(4-(4-(1-(imidazol-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

35

N-Methyl-N-(4-(4-(1-(2-(3,3-dimethallyloxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

5

N-Methyl-N-(4-(4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

10 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

15 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

20 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)benzamide;

25 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

30 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)benzamide;

35 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)benzamide;

5

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

10

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)benzamide;

15 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

20 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

25 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

30 N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;

35

- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)benzamide;
- 5
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- 10
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide;
- 15
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)-3,4,5-trimethoxybenzamide;
- 20
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;
- 25
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;
- 30
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;
- 35
- N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

5

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

10

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

15

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-methoxyphenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

20

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

25 N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

30 N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

35

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

10 N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

15

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

20

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

25

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

30 N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

35



N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

10 N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-  
15 benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-  
20 methoxy-5-(4H-triazol-4-yl)benzamide;

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

25

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

30 N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-difluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

N-Methyl-N-(4-(4-(1-(4,4,4-trifluorobutyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

35

N-Methyl-N-(4-(4-(1-(allyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

5

N-Methyl-N-(4-(4-(1-(allyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

10 N-Methyl-N-(4-(4-(1-(allyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

N-Methyl-N-(4-(4-(1-(allyl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

15

N-Methyl-N-(4-(4-(1-(allyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

20

N-Methyl-N-(4-(4-(1-(allyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

25

N-Methyl-N-(4-(4-(1-(but-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

30 N-Methyl-N-(4-(4-(1-(but-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

N-Methyl-N-(4-(4-(1-(but-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

35

N-Methyl-N-(4-(4-(1-(but-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

5

N-Methyl-N-(4-(4-(1-(but-2-en-1-yl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

10 N-Methyl-N-(4-(4-(1-(but-2-en-1-yl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide;

N-Methyl-N-(4-(4-(1-(3-methylbut-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide;

15

N-Methyl-N-(4-(4-(1-(3-methylbut-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)-3,4,5-trimethoxybenzamide;

20

N-Methyl-N-(4-(4-(1-(3-methylbut-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide;

25

N-Methyl-N-(4-(4-(1-(3-methylbut-2-en-1-yl)-1H-benzimidazole-2-carbonyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide;

30

N-Methyl-N-(4-(4-(1-(3-methylbut-2-en-1-yl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide;

35

N-Methyl-N-(4-(4-(1-(3-methylbut-2-en-1-yl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide.

A general synthetic procedure for preparing these compounds of formula (1) is set forth in Reaction Scheme A. The reagents and starting materials are readily available to one of ordinary skill in the art. In Reaction Scheme A, all substituents, unless otherwise indicated, are as previously defined.

15


20

25

30

35

## Reaction Scheme A



- In Reaction Scheme A, step 1, the hydroxy group of an appropriate alcohol of structure 2 is converted to an appropriate leaving group to give a compound of structure 2a. An appropriate alcohol of structure 2 is one in which the stereochemistry is as desired in the final product of formula (1) and R', R'', and Ar<sub>1</sub> are as desired in the final product of formula (1). Alternately, an appropriate alcohol of structure 2 can be one in which the stereochemistry gives rise after resolution to stereochemistry as desired in the final product of formula (1) and R', R', and Ar<sub>1</sub> are as desired in the final product of formula (1). An appropriate alcohol of structure 2 can also be one in which the stereochemistry and R' and R' are as desired in the final product of formula (1) and Ar<sub>1</sub> gives rise upon deprotection to Ar<sub>1</sub> as desired in the final product of formula (1). Alternately, an appropriate alcohol of structure 2 can also be one in which the stereochemistry gives rise after resolution to stereochemistry as desired in the final product of formula (1), R' and R'' are as desired in the final product of formula (1), and Ar<sub>1</sub> gives rise upon deprotection to Ar<sub>1</sub> as desired in the final product of formula (1).
- 25 An appropriate alcohol of structure 2 can be prepared by methods described herein and by methods which are well known and appreciated in the art, such as U.S. Patent Nos. 5,317,020 and 5,236,921, which are hereby incorporated by reference; European Patent Application Nos. 0 428 434, published 22 May 1991, 0 630 887, published 28 December 1994, and 0 559 538, published 8 September 1993; PCT Application Nos. WO 9417045, published 4 August 1994 and WO 95415961, published 15 June 1995. and Bioorganic & Medicinal Chemistry Letters, 3, 925-930 (1993).
- 35 An appropriate leaving group, L<sub>1</sub>, is one which can be displaced by a piperidine of structure 3 to give rise to a compound of formula (1). Appropriate leaving groups, L<sub>1</sub>,

include but are not limited to chloro, bromo, iodo, mesylate, tosylate, benzenesulfonate, and the like. The conversion of hydroxy groups to leaving groups such as  
5 chloro, bromo, iodo, mesylate, tosylate, and benzenesulfonate is well known and appreciated in the art.

For example, compounds in which L<sub>1</sub> is bromo are formed by contacting an appropriate alcohol of structure 2 with  
10 1.0 to 1.5 molar equivalents of carbon tetrabromide and 1.0 to 1.75 molar equivalents triphenylphosphine. (P. J. Kocienski et al. J. Org. Chem., 42, 353-355 (1977)). The reaction is carried out by combining the alcohol of structure 2 with carbon tetrabromide in a suitable solvent,  
15 such as dichloromethane or chloroform and then adding a solution of triphenylphosphine in a suitable solvent, such as dichloromethane or chloroform. Generally the reaction is carried out at temperatures of from -10°C to ambient temperature. Generally, the reactions require from 5  
20 minutes to 24 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

25 Compounds in which L<sub>1</sub> is bromo are also formed by contacting an appropriate alcohol of structure 2 with a slight molar excess of triphenylphosphine dibromide. (R. F Borch et al. J. Am. Chem. Soc., 99, 1612-1619 (1977)). The reaction may be carried out by contacting an appropriate  
30 alcohol of structure 2 with preformed triphenylphosphine dibromide. The reaction is carried out in a suitable solvent, such as tetrahydrofuran and diethyl ether. The reaction is carried out in the presence of a suitable base, such as pyridine. Generally the reaction is carried out at  
35 temperatures of from 0°C to 50°C. Generally, the reactions require from 5 minutes to 24 hours. The product can be isolated and purified by techniques well known in the art,

-46-

such as extraction, vaporation, trituration, chromatography, and recrystallization.

- 5 Alternately, for example, compounds in which  $L_1$  is mesylate are formed by contacting an appropriate alcohol of structure 2 with a molar excess of methanesulfonyl chloride. The reaction is carried out in a suitable solvent, such as dichloromethane, chloroform, toluene,  
10 benzene, or pyridine. The reaction is carried out in the presence of a suitable base, such as triethylamine, diisopropylethylamine, or pyridine. Generally the reaction is carried out at temperatures of from  $-20^{\circ}\text{C}$  to  $50^{\circ}\text{C}$ . Generally, the reactions require from 1 hour to 24 hours.  
15 The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

- Compounds of structure 2a in which  $L_1$  is iodo can be  
20 prepared from compounds of structure 2a in which  $L_1$  is mesylate, chloro, or bromo by an exchange reaction, such as the Finkelstein reaction.

- For example, a compound of structure 2a in which  $L_1$  is  
25 mesylate, chloro, or bromo is contacted with from 1.0 to 10.0 molar equivalents of an iodide salt, such as sodium iodide or potassium iodide. The reaction is carried out in a suitable solvent, such as acetone, butanone, tetrahydrofuran, tetrahydrofuran/water mixtures, toluene,  
30 and acetonitrile. Generally, the reaction is carried out at temperatures of from ambient temperature to the refluxing temperature of the solvent. Generally, the reactions require from 1 hour to 24 hours. The product can be isolated and purified by techniques well known in the  
35 art, such as extraction, evaporation, trituration, chromatography, and recrystallization.



In Reaction Scheme A, step 2, the compound of structure 2a reacts with an appropriate piperidine compound of structure 3 or a salt thereof to give a protected compound of formula (1) or a compound of formula (1).

An appropriate piperidine of structure 3 or salt thereof is one in which  $X_1$  and  $X_2$  are as desired in the final product of formula (1) or  $X_1$  and  $X_2$  give rise after modification or deprotection to  $X_1$  and  $X_2$  are as desired in the final product of formula (1). Appropriate piperidines of structure 3 are well known and appreciated in the art and are described in International Patent Application (PCT) No. WO 92/06086, United States Patent No. 4,908,372, March 13, 1990, United States Patent No. 4,254,129, March 3, 1981, United States Patent No. 4,254,130, March 3, 1981, United States Patent No. 4,285,958, April 25, 1981, United States Patent No. 4,550,116, October 29, 1985, and European Patent Application No. 0 533 344, published March 24, 1993; and by methods analogous to those methods by carrying out suitable deprotections, protections, and alkylations, as are well known in the art, in the order and number required for formation of an appropriate piperidine of structure 3. Appropriate piperidines of structure 3 wherein  $X_1$  and  $Z_1$  taken together form a second bond between the carbon atoms bearing  $X_1$  and  $Z_1$  may be prepared by dehydration of the corresponding compound wherein  $X_1$  is hydroxy by procedures generally known in the art, such as refluxing in strongly acidic solution. Appropriate piperidines of structure 3 may also be prepared by addition of readily available organometallic reagents to suitably protected 4-piperidinones or suitably protected isonipecotic acid derivatives, by methods known in the art such as described by G. D. Maynard *et al.*, Bioorg. and Med. Chem. Lett., **3**, 753-756 (1993). Appropriate piperidines of structure 3 may also be prepared from readily available starting materials or by methods known analogously in the art, such as described by C. G. Wahlgren and A. W. Addison, J.

- Heterocyclic Chem., 26, 541 (1989), R. Iemura and H. Ohtka,  
Chem. Pharm. Bull., 37, 967-972 (1989), and K. Ito and G.  
Tsukamoto, J. Heterocyclic Chem., 24, 31 (1987), by
- 5 carrying out suitable deprotections, protections, and  
alkylations, as are well known in the art, in the order and  
number required for formation of an appropriate piperidine  
of structure 3.
- 10 For example, the compound of structure 2a is contacted  
with an appropriate piperidine compound of structure 3 or  
salt thereof to give a protected compound of formula (1) or  
a compound of formula (1). The reaction is carried out in  
a suitable solvent, such as dioxane, tetrahydrofuran,  
15 tetrahydrofuran/water mixtures, acetone, acetone/water  
mixtures, ethyl acetate, ethyl acetate/water mixtures,  
pyridine, acetonitrile, toluene, toluene/water mixtures,  
chlorobenzene, or dimethylformamide. The reaction is  
carried out in the presence of from 1.0 to 6.0 molar  
20 equivalents of a suitable base, such as sodium carbonate,  
sodium bicarbonate, potassium carbonate, potassium  
bicarbonate, triethylamine, pyridine, or  
diisopropylethylamine. When a salt of an appropriate  
piperidine of structure 3 is used, an additional molar  
25 excess of a suitable base may be required. The reaction  
may be facilitated by the addition of a catalytic amount,  
0.1 to 0.5 molar equivalents, of an iodide salt, such as  
sodium iodide, potassium iodide, or tetrabutyl ammonium  
iodide. The reaction is generally carried out at  
30 temperatures of from ambient temperature to the refluxing  
temperature of the solvent. Generally, the reactions  
require 1 to 72 hours. The product can be isolated and  
purified by techniques well known in the art, such as  
extraction, evaporation, trituration, chromatography, and  
35 recrystallization.

In Reaction Scheme A, optional step 3, a compound of  
formula (1) or a protected compound of formula (1) in which

Z is hydrogen is modified to give a compound of formula (1) or a protected compound of formula (1) in which Z is not hydrogen. Also encompassed by Reaction Scheme A, optional step 3, a protected compound of formula (1) is deprotected to give a compound of formula (1).

A modification reaction encompasses the formation of amides and the alkylation of the benzimidazole nitrogen. The formation of amides from esters and acids is well known and appreciated in the art. The alkylation of a benzimidazole nitrogen using a suitable alkylating agent is well known and appreciated in the art. The reaction is carried out in a suitable solvent, such as dioxane, tetrahydrofuran, tetrahydrofuran/water mixtures, acetone, or acetonitrile. A suitable alkylating agent is one which transfers the group Z or  $(CH_2)_pAr_2$  as desired in the final product of formula (1) or a protected group Z or  $(CH_2)_pAr_2$  which gives rise after deprotection to Z or  $(CH_2)_pAr_2$  as desired in the final product of formula (1). The reaction is carried out in the presence of from 1.0 to 6.0 molar equivalents of a suitable base, such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, triethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 1,5-diazabicyclo[4.3.0]non-5-ene, potassium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, or diisopropylethylamine. The reaction is generally carried out at temperatures of from ambient temperature to the refluxing temperature of the solvent. Generally, the reactions require 1 to 72 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

Alternately, the compounds of formula (1) or a protected compound of formula (1) in which Z is hydrogen and having a benzimidazole-2-carbonyl can be alkylated by the Mitsunobu reaction using a suitable alcohol. A

suitable alcohol is one which transfers the group Z or  $(CH_2)_pAr_2$  as desired in the final product of formula (1) or a protected group Z or  $(CH_2)_pAr_2$  which gives rise after  
5 deprotection to Z or  $(CH_2)_pAr_2$  as desired in the final product of formula (1).

A deprotection reaction, such as the removal of hydroxy protecting groups or hydrolysis of an ester, utilizing  
10 suitable protecting groups such as those described in Protecting Groups in Organic Synthesis by T. Greene is well known and appreciated in the art.

A general synthetic procedure for preparing the  
15 alcohols of formula 2 is set forth in Reaction Scheme B. The reagents and starting materials are readily available to one of ordinary skill in the art. In Scheme B, all substituents, unless otherwise indicated, are as previously defined.


20

25

30

35

## Reaction Scheme B



In Reaction Scheme B, step 1, an appropriate nitrile of structure 5 is alkylated with an appropriate protected alcohol of structure 4 to give an 4-(protected-hydroxy)butyronitrile of structure 6.

An appropriate nitrile of structure 5 is one in which  $\text{Ar}_1$  is as desired in the final product of formula (1) or  $\text{Ar}_1$  gives rise after deprotection to  $\text{Ar}_1$  as desired in the final product of formula (1). An appropriate protected alcohol

of structure 4 is one in which the leaving group,  $L_2$ , can be displaced by an anion derived from an appropriate nitrile of structure 5. Suitable leaving groups include but are not limited to chloro, bromo, iodo, and mesylate with bromo and iodo being preferred. The selection and use of a suitable hydroxy protecting group,  $Pg_1$ , such as those described in Protecting Groups in Organic Synthesis by T. Greene are well known and appreciated in the art. The use of tetrahydropyran-2-yl and t-butyldimethylsilyl hydroxy protecting groups are generally preferred.

For example, the appropriate nitrile of structure 5 is contacted with 0.8 to 1.2 molar equivalents of the appropriate protected alcohol of structure 4 under phase transfer catalysis conditions. The reaction is carried out in the presence of a 2 to 10 fold molar excess of a suitable base, such as sodium hydroxide or potassium hydroxide. The reaction is carried out in a solvent, such as water, ethyl acetate/water mixtures, dichloromethane/water mixtures, or tetrahydrofuran/water mixtures. The reaction is carried out in the presence of a suitable phase transfer catalyst, such as benzyltriethylammonium chloride, benzyltriethylammonium bromide, benzyltriethylammonium iodide, benzyltrimethylammonium chloride, benzyltributylammonium chloride, tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium iodide, tetrabutylammonium hydrogen sulfate, and the like. The reaction is generally carried out at temperatures of from  $-20^{\circ}\text{C}$  to  $60^{\circ}\text{C}$ . Generally, the reactions require 1 to 72 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

Alternately, for example, the appropriate nitrile of structure 5 is contacted with 1.0 to 1.2 molar equivalents of the appropriate protected alcohol of structure 4. The

reaction is carried out in the presence of an equimolar amount of a suitable base, such as sodium hydride, sodium bis(trimethylsilyl)amide, potassium  
5 bis(trimethylsilyl)amide, potassium t-butoxide, s-butyl lithium, and lithium diisopropylamide. The reaction is carried out in a solvent, such as dimethylformamide or tetrahydrofuran. The reaction is generally carried out at temperatures of from -78°C to 0°C. Generally, the  
10 reactions require 1 to 72 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, distillation, trituration, chromatography, and recrystallization.

15 In Reaction Scheme B, step 2, the 4-(protected-hydroxy)butyronitrile of structure 6 is reduced to give an amino compound of structure 7.

For example, the 4-(protected-hydroxy)butyronitrile of  
20 structure 6 is contacted with an excess of an appropriate reducing agent, such as sodium borohydride in the presence of cobalt (II) chloride hexahydrate or hydrogen in the presence of a suitable catalyst, such as Raney nickel or platinum oxide. For compounds of structure 6 in which Ar<sub>1</sub>  
25 is thienyl or pyridyl, sodium borohydride in the presence of cobalt (II) chloride hexahydrate is preferred.

When sodium borohydride in the presence of cobalt chloride is used, the reaction is carried out in a suitable  
30 solvent, such as methanol, or ethanol. The reaction is generally carried out at temperatures of from 0°C to 50°C. Generally, the reactions require 1 to 72 hours. The product can be isolated and purified by techniques well known in the art, such as extraction with aqueous acid,  
35 evaporation, trituration, distillation, chromatography, and recrystallization.

When Raney nickel is used, the reaction is carried out in a suitable solvent containing ammonia, such as ethanol/aqueous ammonium hydroxide or methanol/aqueous ammonium hydroxide. The reaction is generally carried out at temperatures of from ambient temperature to 70°C. The reaction is carried out with hydrogen at pressures of from 15 psi to 120 psi in an apparatus designed for carrying out reactions under pressure, such as a Parr hydrogenation apparatus. The product can be isolated by carefully removing the catalyst by filtration and evaporation. The product can be purified by extraction, evaporation, trituration, chromatography, and recrystallization.

When platinum oxide is used, the reaction is carried out in a suitable solvent such as ethanol, methanol, chloroform, ethanol/chloroform mixtures, or methanol/chloroform mixtures. The reaction is generally carried out at temperatures of from ambient temperature to 50°C. The reaction is carried out with hydrogen at pressures of from 15 psi to 120 psi in an apparatus designed for carrying out reactions under pressure, such as a Parr hydrogenation apparatus. Generally, the reaction requires 8 to 48 hours. The product can be purified by extraction, evaporation, trituration, chromatography, and recrystallization.

In Reaction Scheme B, step 3, the amino compound of structure 7 is benzoylated with an appropriate benzoylating agent to give a benzamide of structure 8. An appropriate benzoylating agent is an agent capable of transferring a benzoyl group or substituted benzoyl group, such as a benzoyl halide, substituted benzoyl halide, benzoyl anhydride, substituted benzoyl anhydride, benzoyl mixed anhydride, or substituted benzoyl mixed anhydride to give a benzamide of structure 8. An appropriate benzoylating agent gives a benzamide of structure 8 in which R' and R" are as desired in the final product of formula (1).



For example, the amino compound of structure 7 is contacted with 1 to 1.5 molar equivalents of an appropriate benzoylating agent. The reaction is carried out in a suitable solvent, such as dichloromethane, tetrahydrofuran, acetonitrile, dimethylformamide, or pyridine. The reaction is carried out in the presence of a base, such as sodium carbonate, sodium bicarbonate, triethylamine, N-methylmorpholine, diisopropylethylamine, or pyridine. The reaction is generally carried out at temperatures of from -20°C to 50°C. Generally, the reactions require 1 to 6 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

Alternately, for example, the amino compound of structure 7 is contacted with 1 to 1.5 molar equivalents of an appropriate benzoylating agent under Schotten-Baumann conditions. The reaction is carried out in a suitable solvent, such as ethyl acetate/water mixtures, acetone/water mixtures, tetrahydrofuran/water mixtures, or dichloromethane/water mixtures. The reaction is carried out in the presence of a base, such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, or sodium hydroxide. The reaction is generally carried out at temperatures of from 0°C to the refluxing temperature of the solvent. Generally, the reactions require 1 to 6 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

In Reaction Scheme B, step 4, a benzamide of structure 8 is methylated with an appropriate methylating agent to give a N-methylbenzamide of structure 9. An appropriate methylating agent is one that transfers a methyl to a

benzamide of structure 8, including iodomethane, bromomethane, dimethylsulfate, trimethyloxonium tetrafluoroborate, and the like.

5

For example, a benzamide of structure 8 is contacted with 1 to 4 molar equivalents of the appropriate methylating agent. The reaction is carried out in the presence of from 1 to 4 molar equivalents of a suitable base, such as n-butyl lithium, sec-butyl lithium, sodium hydride, sodium bis(trimethylsilyl)amide, potassium t-butoxide, and lithium diisopropylamide with sodium hydride, sodium bis(trimethylsilyl)amide, and sec-butyl lithium being preferred. The reaction is carried out in a solvent, such as dimethylformamide or tetrahydrofuran. The reaction is generally carried out at temperatures of from -20°C to 60°C. Generally, the reactions require 1 to 72 hours. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, trituration, chromatography, and recrystallization.

In Reaction Scheme B, step 5, the N-methylbenzamide of structure 9 is deprotected to give an alcohol of structure 2. A deprotection reaction, such as the removal of hydroxy protecting groups utilizing suitable protecting groups such as those described in Protecting Groups in Organic Synthesis by T. Greene is well known and appreciated in the art.

30

35

The following examples and preparations present typical syntheses of the compounds of formula (1). These examples are understood to be illustrative only and are not intended to limit the scope of the invention in any way.

#### PREPARATION 1

##### Synthesis of 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt

10        Combine piperidine-4-carboxylic acid (500 g), water (4.2 L), t-butanol (4 L), and 50% aqueous sodium hydroxide solution (386 g). Add portionwise, di-t-butyldicarbonate (930 g). After 20 hours, concentrate the reaction mixture *in vacuo* to about one half the volume. Slowly add 10% aqueous  
15        hydrochloride solution until the pH is about 4. Extract with diethyl ether (3 X 4L). Dry the organic layer over MgSO<sub>4</sub>, filter and evaporate on a steam bath to a volume of about 4 L. Add ethyl acetate (4 L) and evaporate on a steam bath to a volume of about 4 L. Filter and continue  
20        to evaporate on a steam bath to a volume of about 2 L. Cool and filter to obtain 1-(t-butoxycarbonyl)piperidine-4-carboxylic acid.

          Combine 1-(t-butoxycarbonyl)piperidine-4-carboxylic acid (813.7 g) and dichloromethane (6 L). Add portionwise,  
25        carbonyldiimidazole (633.1 g). After 1 hour, add N-methyl-O-methylhydroxylamine hydrochloride (380.5 g). After 56 hours, extract the reaction mixture with 5% aqueous hydrochloric acid solution and 5% aqueous sodium bicarbonate solution. Dry the organic layer over MgSO<sub>4</sub>,  
30        filter, and evaporate *in vacuo* to obtain 1-(t-butoxycarbonyl)piperidine-4-(N-methyl-O-methyl)hydroxamic acid.

          Combine benzimidazole (57.8 g, 490 mmol) and dimethylformamide (570 mL). Cool using an ice bath to  
35        about 20°C. Add portionwise, sodium hydride (20.2 g, 60% in oil, 500 mmol) at such a rate that the temperature of the reaction mixture remains at about 20°C. After the addition of sodium hydride is complete, allow to stir for 1

hour. Add a solution of 2-(trimethylsilyl)ethoxymethyl chloride (60 g, 360 mmol) in dimethylformamide (60 mL) at such a rate that the temperature of the reaction mixture remains below 20°C. After 18 hours, add dropwise, water (50 mL). When the addition is complete, pour the reaction mixture into water (2 L). Extract repeatedly with diethyl ether. Combine the organic layers and extract with water. Dry the organic layer over MgSO<sub>4</sub>, filter, and evaporate *in vacuo* to obtain 1-((2-trimethylsilyl)ethoxymethyl)-1H-benzimidazole.

Combine 1-((2-trimethylsilyl)ethoxymethyl)-1H-benzimidazole (91.2 g, 367 mmol) and tetrahydrofuran (500 mL). Cool to -78°C using a dry-ice/acetone bath. Add a solution of n-butyllithium (146 mL, 2.5 M in hexane, 367 mmol) at such a rate that the temperature of the reaction mixture remains at about -70°C. After the addition of n-butyllithium is complete allow to stir for 30 minutes at -78°C. Add dropwise, a solution of 1-(t-butoxycarbonyl)piperidine-4-(N-methyl-O-methyl)hydroxamic acid (99.9 g, 367 mmol) in tetrahydrofuran (100 mL). Warm to ambient temperature. After 18 hours, add dropwise a saturated aqueous ammonium chloride solution (100 mL). Add water (300 mL) and extract with diethyl ether. Dry the organic layer over MgSO<sub>4</sub>, filter, and evaporate *in vacuo* to obtain a residue. Chromatograph the residue on silica gel eluting with 10 % ethyl acetate/hexane to give a residue. Recrystallize the residue from methanol/water to give 1-(t-butoxycarbonyl)-4-(1-((2-trimethylsilyl)ethoxymethyl)-1H-benzimidazole-2-carbonyl)piperidine.

Add portionwise, 1-(t-butoxycarbonyl)-4-(1-((2-trimethylsilyl)ethoxymethyl)-1H-benzimidazole-2-carbonyl)piperidine (20.0 g, 43.5 mmol) to aqueous hydriodic acid (48%, 140 mL). After the addition is complete, heat to 50°C. After 1.5 hours, cool to ambient temperature. After 2.5 hours, extract twice with diethyl ether. Add diethyl ether (300 mL) and isopropanol (60 mL) to the aqueous layer to give a solid. Collect the solid by

filtration and rinse with diethyl ether to give, after drying, the title compound. Elemental Analysis calculated for  $C_{13}H_{15}N_3O \cdot 2 HI$ : C 32.19; H 3.53; N 8.66; Found: C 32.34; H 3.37; N 8.48.

#### PREPARATION 2

##### Synthesis of 1-(t-butoxycarbonyl)-4-(1H-benzimidazole-2-carbonyl)piperidine

10        Combine 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt (9.17 g, 18.9 mmol) and t-butanol (100 mL). Add an aqueous solution of sodium bicarbonate (40 mL, 1 M, 40 mmol). Add di-t-butyldicarbonate (5.2 g, 23.9 mmol). After 72 hours, concentrate *in vacuo* to give a  
15        residue. Combine the residue and ethyl acetate. Extract with aqueous 1 M hydrochloric acid solution, saturated aqueous sodium bicarbonate solution, 0.5 M aqueous sodium thiosulfate solution, and brine. Dry the separated organic layer over  $Na_2SO_4$ , filter, and evaporate *in vacuo* to give a  
20        solid. Triturate the solid with diethyl ether, collect the solid by filtration, and recrystallize from ethyl acetate to give, after collection and drying, the title compound: mp; 226-228°C.  $R_f=0.30$  (silica gel, 20% ethyl acetate/hexane).

25

#### PREPARATION 3

##### Synthesis of 4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt

30        Combine 1-(t-butoxycarbonyl)-4-(1H-benzimidazole-2-carbonyl)piperidine (2.0 g, 6.1 mmol) and 2-(chloromethyl)pyridine (2.32 g, 18.2 mmol) (obtained by combining 2-(chloromethyl)pyridine hydrochloride, sodium carbonate, and dichloromethane with stirring followed by filtration and evaporation) and potassium carbonate (4.2 g,  
35        30.4 mmol) in acetone (40 mL) and water (10 mL). Heat to reflux. After 24 hours, cool to ambient temperature and dilute with ethyl acetate. Extract with water and brine. Dry the organic layer over  $MgSO_4$ , filter, and concentrate *in*

*vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 50% ethyl acetate/hexane to give, after drying, 1-(*t*-butoxycarbonyl)-4-(1-(pyrid-2-ylmethyl)-1*H*-benzimidazole-2-carbonyl)piperidine: mp; 45-50°C. *R*<sub>f</sub>=0.24 (silica gel, 40% ethyl acetate/hexane). Elemental Analysis calculated for C<sub>24</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>: C 68.08; H 6.74; N 13.23; Found: C 67.88; H 6.68; N 13.00.

Combine 1-(*t*-butoxycarbonyl)-4-(1-(pyrid-2-ylmethyl)-1*H*-benzimidazole-2-carbonyl)piperidine (1.96 g, 4.7 mmol) and dichloromethane (150 mL). Cool to 0°C using an ice bath. Add hydriodic acid (gas) until the solution is saturated and stir. After 30 minutes, again add hydriodic acid (gas) until the solution is saturated. After 2 hours, evaporate *in vacuo* to give, after drying, the title compound: mp 165-167°C.

#### PREPARATION 4

##### Synthesis of 1-(*t*-butyldimethylsilyloxy)-2-bromoethane

Combine imidazole (59.9 g, 880 mmol), *t*-butyldimethylsilyl chloride (60.3 g, 400 mmol), and dimethylformamide (300 mL). Cool to 0°C in a salt-ice bath. Add dropwise 2-bromoethanol (50.0 g, 400 mmol) at such a rate that the temperature of the reaction mixture does not rise above 0°C. After 2 hours, warm to ambient temperature. After 18 hours, extract the reaction mixture three times with hexane. Combine the hexane layers and extract three times with a saturated aqueous solution of ammonium chloride, three times with a saturated aqueous solution of sodium bicarbonate, and then brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give the title compound.


#### PREPARATION 5

##### Synthesis of 1-(*t*-butyldimethylsilyloxy)-2-iodoethane

Prepare by the method of Preparation 4 using 2-iodoethanol to give the title compound.

EXAMPLE 1

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-  
5 trimethoxybenzamide



1.1.1 Synthesis of 2-(4-fluorophenyl)-4-(t-  
butyldimethylsilyloxy)butyronitrile

As adapted from the procedure of Org. Syn. Collective  
20 Volume VI, 897-900 (1988), combine 4-  
fluorophenylacetonitrile (56.5 g, 418 mmol), an aqueous 50%  
sodium hydroxide solution (106.3 g, 1330 mmol), and  
benzyltriethylammonium chloride (0.95 g) in water (100 mL).  
Warm to about 30°C and stir vigorously. Add dropwise over  
25 about 30 minutes 1-(t-butyldimethylsilyloxy)-2-bromoethane  
(50 g, 209 mmol). When the addition is complete, warm to  
about 40°C and continue to stir vigorously. After 18  
hours, dilute the reaction mixture with ethyl acetate and  
stir. After 30 minutes, separate the organic layer and  
30 extract three times with aqueous saturated ammonium  
chloride solution, two times with an aqueous saturated  
sodium bicarbonate solution, and then brine. Dry the  
organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *in vacuo*  
to give a residue. Distill the residue to give the title  
35 compound: bp; 100-115°C at 0.2 mm Hg. R<sub>f</sub>=0.35 (silica gel,  
1/1 dichloromethane/hexane).

1.1.2 Synthesis of 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyronitrile

Combine 4-fluorophenylacetonitrile (5.0 g, 37.0 mmol),  
5 and tetrahydrofuran (45 mL). Cool to about -65°C using a  
dry-ice/acetone bath. Add a solution of potassium bis-  
(trimethylsilyl)amide (89 mL, 0.5 M in toluene, 44.5 mmol).  
After 1 hour, add a solution of 1-(t-  
butyldimethylsilyloxy)-2-iodoethane (12.7 g, 44.4 mmol) in  
10 tetrahydrofuran (10 mL). After the addition of 1-(t-  
butyldimethylsilyloxy)-2-iodoethane is complete, warm to  
ambient temperature. After 18 hours, dilute the reaction  
mixture with tetrahydrofuran and extract three times with  
aqueous saturated ammonium chloride solution and then twice  
15 with brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and  
concentrate *in vacuo* to give a residue. Chromatograph the  
residue on silica gel eluting with 1/1  
dichloromethane/hexane to give the title compound.

20 1.1.3 Synthesis of 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyronitrile

Combine 4-fluorophenylacetonitrile (1.0 g, 7.4 mmol),  
and tetrahydrofuran (9 mL). Cool to about -70°C using a  
dry-ice/acetone bath. Add a solution of potassium bis-  
25 (trimethylsilyl)amide (14.8 mL, 0.5 M in toluene, 7.4  
mmol). After 2 hours, add, via cannula, the solution  
prepared above to a cooled (-25°C) solution of 1-(t-  
butyldimethylsilyloxy)-2-iodoethane (2.1 g, 7.4 mmol) in  
tetrahydrofuran (4 mL). After the addition to 1-(t-  
30 butyldimethylsilyloxy)-2-iodoethane is complete, warm to  
ambient temperature. After 18 hours, dilute the reaction  
mixture with tetrahydrofuran and extract three times with  
aqueous saturated ammonium chloride solution and then twice  
with brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and  
35 concentrate *in vacuo* to give a residue. Chromatograph the  
residue on silica gel eluting with 1/1  
dichloromethane/hexane to give the title compound.



1.1.4 Synthesis of 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyronitrile

Combine 4-fluorophenylacetonitrile (1.0 g, 7.4 mmol),  
5 and tetrahydrofuran (20 mL). Cool to about -70°C using a  
dry-ice/acetone bath. Add a solution of s-butyl lithium  
(6.3 mL, 1.3 M in cyclohexane, 8.1 mmol). After 1 hour,  
add a solution of 1-(t-butyldimethylsilyloxy)-2-iodoethane  
(2.1 g, 7.4 mmol) in tetrahydrofuran (4 mL). After 2  
10 hours, warm to ambient temperature. After 18 hours, dilute  
the reaction mixture with ethyl acetate and extract twice  
with aqueous saturated ammonium chloride solution and then  
twice with brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>,  
filter, and concentrate *in vacuo* to give a residue.  
15 Chromatograph the residue on silica gel eluting with 1/1  
dichloromethane/hexane to give the title compound.

1.2 Synthesis of 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butylamine

20 Combine 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyronitrile (43.0 g, 146.5 mmol)  
and ethanol (200 mL) in a Parr bottle. Add Raney nickel  
(129 g) to the reaction mixture. Add a solution of  
concentrated ammonium hydroxide (40 mL). Hydrogenate on a  
25 Parr shaker at 50 psi. After 24 hours, filter through a  
celite pad and rinse the solids with ethanol. Concentrate  
the filtrate *in vacuo* to give the title compound.

1.3 Synthesis of N-(2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

30 Combine 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butylamine (7.33 g, 24.6 mmol) and  
sodium carbonate (2.61 g, 24.6 mmol) in 4/1 ethyl  
acetate/water (400 mL). Cool the reaction mixture to 0°C  
35 with a salt-ice bath. Slowly, add a solution of 3,4,5-  
trimethoxybenzoyl chloride (5.96, 25.9 mmol) in ethyl  
acetate (50 mL) at such a rate that the temperature of the  
reaction mixture does not rise above 5°C. After 2 hours,

warm to ambient temperature. After 18 hours, separate the layers and extract the organic layer twice with a saturated aqueous solution of ammonium chloride, twice with a  
5 saturated aqueous solution of sodium bicarbonate and then with brine. Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and concentrate *in vacuo* to obtain a residue. Chromatograph the residue on silica gel eluting with 50% ethyl acetate/hexane to give, after drying, the title compound: mp; 113-114°C.  
10  $R_f=0.30$  (silica gel, 50% ethyl acetate/hexane). Elemental Analysis calculated for  $\text{C}_{26}\text{H}_{38}\text{FNO}_3\text{Si}$ : C 63.51; H 7.79; N 2.85; Found: C 63.43; H 7.51; N 2.66.

1.4 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-(t-butyl)dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Combine hexane washed sodium hydride (0.48 g, 50% in oil, 10.0 mmol) and dimethylformamide (5 mL). Cool the reaction mixture to 0°C with a salt-ice bath. Slowly, add a solution of N-(2-(4-fluorophenyl)-4-(t-  
20 butyl)dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide (4.0 g, 8.1 mmol) in dimethylformamide (10 mL). Stir until gas evolution ceases. Add iodomethane (0.62 mL, 10.0 mmol). After 16 hours, dilute the reaction mixture with ethyl acetate and extract three times with water and then brine.  
25 Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and concentrate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 1/1 ethyl acetate/hexane to give, after drying, the title compound:  $R_f=0.15$  (silica gel, 1/1 ethyl acetate/hexane). Elemental Analysis calculated for  
30  $\text{C}_{27}\text{H}_{40}\text{FNO}_3\text{Si}$ : C 64.13; H 7.97; N 2.77; Found: C 63.73; H 7.90; N 2.88.

1.5 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide

35 Combine N-methyl-N-(2-(4-fluorophenyl)-4-(t-butyl)dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide (3.9 g, 7.65 mmol) and methanol (40 mL). Add ammonium fluoride (1.71 g, 46.0 mmol). Heat to reflux. After 20 hours,

concentrate *invacuo* to give a residue. Combine the residue with water and dichloromethane. Separate the layers and extract the aqueous layer twice with dichloromethane.

- 5 Combine the organic layers and dry over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *invacuo* to give the title compound: mp; 30-35°C. R<sub>f</sub>=0.30 (silica gel, 10/1 ethyl acetate/methanol).

10 1.6 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

- Combine N-methyl-N-(2-(4-fluorophenyl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide (2.5 g, 6.36 mmol), diisopropylethylamine (2.4 mL, 14.0 mmol), and anhydrous dichloromethane (25 mL). Cool the reaction mixture to 0°C  
15 with an ice bath. Slowly, add methanesulfonyl chloride (0.69 mL, 8.9 mmol). After 1 hour, dilute the reaction mixture with dichloromethane and extract 3 times with aqueous 1M hydrochloric acid solution, 2 times with a saturated solution of sodium bicarbonate, and then brine.  
20 Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *invacuo* to obtain the title compound: R<sub>f</sub>=0.43 (silica gel, 10/1 ethyl acetate/methanol).

25 1.7 Synthesis of N-methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide

- Combine N-methyl-N-(2-(4-fluorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide (0.37 g, 0.79 mmol), diisopropylethylamine (1.23 mL, 7.1 mmol), and  
30 4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt (0.83 g, 1.2 mmol) in acetonitrile (15 mL). Heat to reflux. After 18 hours, cool the reaction mixture, dilute with ethyl acetate, and extract with a saturated solution of sodium bicarbonate and  
35 then brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *invacuo* to obtain a residue. Chromatograph the residue on silica gel eluting with 10/0.3/89.7 methanol/aqueous concentrated ammonia

solution/dichloromethane to give, after drying, the title compound.

5

#### PREPARATION 6

##### Synthesis of 1-(tetrahydropyran-2-yloxy)-2-bromoethane

Combine 2-bromoethanol (14.2 mL, 200 mmol) and dihydropyran (18.25 mL, 200 mmol) in dichloromethane (20 mL). Add Pyridinium p-toluenesulfonic acid (5 g, 20 mmol).  
10 After 2.5 hours, dilute the reaction mixture with diethyl ether and extract with water, 1/1 water/brine, water, and then brine. Dry the organic layer over MgSO<sub>4</sub>, filter, and evaporate *in vacuo* to give a residue. Distill the residue to give the title compound: bp; 80-90°C at 15-20 mm Hg.

15


#### EXAMPLE 2

##### N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide

20

25

30



##### 2.1 Synthesis of 2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyronitrile

35

Combine sodium hydride (1.2 g, 50 mmol) and tetrahydrofuran (20 mL). Add dropwise a solution of 3,4-dichlorophenylacetonitrile (8.9 g, 47.8 mmol) in tetrahydrofuran (50 mL) at about 0°C. When the addition is complete, allow to warm to ambient temperature and stir.

After 2.5 hours, cool to 0°C and add 1-(tetrahydropyran-2-yloxy)-2-bromoethane (10.0 g, 47.9 mmol). Warm to ambient temperature. After 16 hours, pour the reaction mixture  
5 into saturated ammonium chloride and extract with diethyl ether. Separate the organic layer and extract with water and brine. Dry the organic layer over MgSO<sub>4</sub>, filter, and concentrate *in vacuo* to give a residue. Chromatograph the  
10 residue on silica gel eluting sequentially with 5% ethyl acetate/hexane, 10% ethyl acetate/hexane, and 20% ethyl acetate in hexane to give the title compound.

#### 2.2 Synthesis of 2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butylamine

15 Combine 2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyronitrile (7 g) and ethanol (20 mL) in a Parr bottle. Add Raney nickel (1 g) to the reaction mixture. Add a solution of concentrated ammonium hydroxide (3.5 mL). Hydrogenate on a Parr shaker at 50 psi. After 24 hours,  
20 filter through a celite pad and rinse the solids with ethanol. Concentrate the filtrate *in vacuo* to obtain a residue. Chromatograph the residue *in vacuo* on silica gel eluting sequentially with 50% ethyl acetate/hexane and 10% methanol/dichloromethane to give the title compound.

25

#### 2.3 Synthesis of N-(2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyl)benzamide

Combine 2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butylamine (3.05 g, 9.6 mmol) and N-methylmorpholine  
30 (2.2 mL, 20 mmol) in anhydrous dichloromethane (25 mL). Cool the reaction mixture to 0°C with a salt-ice bath. Slowly, add benzoyl chloride (1.2 mL, 10.3 mmol). After 1 hour, extract the reaction mixture with a saturated solution of sodium bicarbonate and then water. Dry the  
35 organic layer over MgSO<sub>4</sub>, filter, and concentrate *in vacuo* to obtain a residue. Chromatograph the residue on silica gel eluting sequentially with 35% ethyl acetate/hexane and then with 50% ethyl acetate/hexane to give the title compound.

2.4 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyl)benzamide

5        Combine N-(2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyl)benzamide (3.84 g) and tetrahydrofuran (20 mL). Add sodium hydride (0.28 g, 11.5 mmol) and stir until gas evolution ceases. Add iodomethane (1.5 mL, 24.1 mmol). After 6 hours, dilute the reaction mixture with diethyl  
10 ether and extract with a saturated solution of ammonium chloride. Separate the organic layer and extract with sodium bisulfite solution, water, and brine. Dry the organic layer over  $\text{MgSO}_4$ , filter, and concentrate *in vacuo* to give the title compound.

15

2.5 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)benzamide

Combine N-methyl-N-(2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyl)benzamide (3.7 g) and  
20 methanol (30 mL). Add p-toluenesulfonic acid hydrate (0.73 g) and stir. After 18 hours, concentrate *in vacuo* to give a residue. Combine the residue and dichloromethane and extract with a saturated solution of sodium bicarbonate and then water. Dry the organic layer over  $\text{MgSO}_4$ , filter, and  
25 concentrate *in vacuo* to obtain a residue. Chromatograph the residue on silica gel eluting sequentially with 50% ethyl acetate/hexane and then ethyl acetate to give the title compound.

30 2.6 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)benzamide

Combine N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)benzamide (0.5 g), diisopropylethylamine (0.3 mL, 1.7 mmol), and anhydrous dichloromethane (8 mL). Cool  
35 the reaction mixture to 0°C with an ice bath. Slowly, add methanesulfonyl chloride (0.13 mL, 1.7 mmol). Warm to ambient temperature. After 18 hours, quench the reaction by the addition of ice. Separate the organic layer and

extract 3 times with 1M hydrochloric acid solution and 2 times with a saturated solution of sodium bicarbonate. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *in vacuo* to obtain the title compound.

2.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide

10        Combine N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)benzamide (0.6 g, 1.4 mmol), sodium bicarbonate (0.23 g, 2.8 mmol), and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine trifluoroacetic acid salt (0.63 g, 1.4 mmol) in tetrahydrofuran (15 mL) and  
15        water (5 mL). Heat to reflux. After 3 days, cool the reaction mixture, dilute with ethyl acetate, and extract with water and then brine. Dry the organic layer over MgSO<sub>4</sub>, filter, and concentrate *in vacuo* to obtain a residue. Chromatograph the residue on silica gel eluting with  
20        sequentially with 10% toluene/ethyl acetate and then 10% ethanol/10%toluene/ethyl acetate to give, after drying, the title compound: mp: 65-70°C.


2.8 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide hydrochloride salt

25        Combine N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide (0.71 g, 1.4 mmol) and  
30        methanol (10 mL). Add a saturated solution of hydrochloric acid in diethyl ether (3 mL). Evaporate *in vacuo* to obtain a residue. Combine the residue and butanone (5 mL) and slowly add diethyl ether to give a solid. Collect the solid and dry to give the title compound.

35

EXAMPLE 3

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide



3.1 Synthesis of 2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butyronitrile

Prepare by the method of Example 1.1.1 using 4-methoxyphenylacetonitrile and 1-(t-butyldimethylsilyloxy)-2-bromoethane to give the title compound.

3.2 Synthesis of 2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butylamine

Prepare by the method of Example 1.2 using 2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butyronitrile to give the title compound.

3.3 Synthesis of N-(2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.3 using 2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butylamine and benzoyl chloride to give the title compound.

3.4 Synthesis of N-methyl-N-(2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide



Prepare by the method of Example 1.4 using N-(2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide to give the title compound.

5

3.5 Synthesis of N-methyl-N-(2-(4-methoxyphenyl)-4-hydroxybutyl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(4-methoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide to give the title compound.

10

3.6 Synthesis of N-methyl-N-(2-(4-methoxyphenyl)-4-methanesulfonylbutyl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(4-methoxyphenyl)-4-hydroxybutyl)benzamide and methanesulfonyl chloride to give the title compound.

15

3.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidin-1-yl)-2-(4-methoxyphenyl)butyl)benzamide

20

Prepare by the method of Example 1.7 using N-methyl-N-(2-(4-methoxyphenyl)-4-methanesulfonylbutyl)benzamide and 4-(1-(4-fluorobenzyl)-1H-benzoimidazol-2-yl)-4-hydroxypiperidine to give the title compound.

25

PREPARATION 7

Synthesis of 4-(1-(2-(5-hydroxymethylfur-2-ylmethyl)-4-(1H-benzimidazole-2-carbonyl)piperidine

30

According to the method of P. G. McDougal, et al., J. Org. Chem., 51, 3388-3390 (1986), combine hexane washed sodium hydride (20 mmol) and tetrahydrofuran (40 mL). Slowly add 2,5-furandimethanol (20 mmol). After gas evolution ceases, add t-butyldimethylsilyl chloride (20 mmol) and stir vigorously. After about 1 hour, pour the reaction mixture into diethyl ether and extract with a saturated aqueous solution of sodium carbonate, water, and then brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and

35

evaporate *in vacuo* to give 5-(*t*-butyldimethylsilyloxy)methyl-2-hydroxymethylfuran.


Combine 1-(*t*-butoxycarbonyl)-4-(1*H*-benzimidazole-2-carbonyl)piperidine (10 mmol), 5-(*t*-butyldimethylsilyloxy)methyl-2-hydroxymethylfuran (10 mmol), and triphenylphosphine (10 mmol) in tetrahydrofuran (100 mL). Add diethyl azodicarboxylate (10 mmol). After 18 hours, evaporate the reaction mixture *in vacuo* to give a residue. Partition the residue between ethyl acetate and water. Separate the organic layer and extract with water and brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give a residue. Chromatograph the residue on silica gel to give 1-(*t*-butoxycarbonyl)-4-(1-(5-(*t*-butyldimethylsilyloxy)methylfuran-2-ylmethyl)-1*H*-benzimidazole-2-carbonyl)piperidine.

Combine 1-(*t*-butoxycarbonyl)-4-(1-(5-(*t*-butyldimethylsilyloxy)methylfuran-2-ylmethyl)-1*H*-benzimidazole-2-carbonyl)piperidine (7 mmol) and methanol (40 mL). Add ammonium fluoride (42 mmol). Heat to reflux. After 20 hours, concentrate *in vacuo* to give a residue. Combine the residue with water and dichloromethane. Separate the layers and extract the aqueous layer twice with dichloromethane. Combine the organic layers and dry over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *in vacuo* to give 1-(*t*-butoxycarbonyl)-4-(1-(5-hydroxymethylfuran-2-ylmethyl)-1*H*-benzimidazole-2-carbonyl)piperidine.

Combine 1-(*t*-butoxycarbonyl)-4-(1-(5-hydroxymethylfuran-2-ylmethyl)-1*H*-benzimidazole-2-carbonyl)piperidine (5 mmol) and dioxane (25 mL). Slowly add a solution of hydrochloric acid in dioxane (1.25 mL, 4 M, 5 mmol). After 45 minutes, add diethyl ether and evaporate *in vacuo* to give a residue. Partition the residue between dichloromethane and saturated aqueous sodium bicarbonate solution. Separate the organic layer and extract with brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give the title compound.

EXAMPLE 4

N-Methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-  
benzimidazole)-4-hydroxypiperidin-1-yl)-2-  
5 phenylbutyl)benzamide



4.1 Synthesis of N-methyl-N-(4-(4-(1-(5-hydroxymethylfur-2-  
20 ylmethyl)-1H-benzimidazole)-4-hydroxypiperidin-1-yl)-2-  
phenylbutyl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1-(5-hydroxymethylfur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine to give  
25 the title compound.

30


35

EXAMPLE 5

N-Methyl-N-(4-(4-(benzthiazole-2-carbonyl)piperidin-1-yl)-  
2-(3,4-dichlorophenyl)butyl)benzamide

5

10



15 5.1 Synthesis of N-methyl-N-(4-(4-(benzthiazole-2-  
carbonyl)piperidin-1-yl)-2-(3,4-  
dichlorophenyl)butyl)benzamide

20 Prepare by the method of Example 2.7 using N-methyl-N-  
(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)benzamide  
and 4-(benzthiazole-2-carbonyl)piperidine to give the title  
compound.


25

30

35

EXAMPLE 6

N-Methyl-N-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-2-phenylbutyl)benzamide



6.1 Synthesis of 2-phenyl-4-(t-butyl  
dimethylsilyloxy)butyronitrile

15 Prepare by the method of Example 1.1.1 using phenylacetonitrile and 1-(t-butyl dimethylsilyloxy)-2-bromoethane to give of the title compound.

6.2 Synthesis of 2-phenyl-4-(t-  
butyl dimethylsilyloxy)butylamine

20 Prepare by the method of Example 1.2 using 2-phenyl-4-(t-butyl dimethylsilyloxy)butyronitrile to give the title compound.

6.3 Synthesis of N-(2-phenyl-4-(t-  
butyl dimethylsilyloxy)butyl)benzamide

25 Prepare by the method of Example 1.3 using 2-phenyl-4-(t-butyl dimethylsilyloxy)butylamine and benzoyl chloride to give the title compound.

6.4 Synthesis of N-methyl-N-(2-phenyl-4-(t-  
butyl dimethylsilyloxy)butyl)benzamide

35 Prepare by the method of Example 1.4 using N-(2-phenyl-4-(t-butyl dimethylsilyloxy)butyl)benzamide to give the title compound.

6.5 Synthesis of N-methyl-N-(2-phenyl-4-  
hydroxybutyl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-phenyl-4-(t-butyldimethylsilyloxy)butyl)benzamide to give the title compound.

5

6.6 Synthesis of N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-phenyl-4-hydroxybutyl)benzamide and methanesulfonyl chloride to give the title compound.

10

6.7 Synthesis of N-methyl-N-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-2-phenylbutyl)benzamide

15

Prepare by the method of Example 1.7 using N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide and 4-(hydroxydiphenylmethyl)piperidine to give the title compound.

20


EXAMPLE 7

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide

25

30

35



7.1 Synthesis of 2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butyronitrile

Prepare by the method of Example 1.1.1 using 3,4-dimethoxyphenylacetonitrile and 1-(t-butyldimethylsilyloxy)-2-bromoethane to give of the title  
5 compound.

7.2 Synthesis of 2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butylamine

Prepare by the method of Example 1.2 using 2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butyronitrile  
10 to give the title compound.

7.3 Synthesis of N-(2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.3 using 2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butylamine and benzoyl chloride to give the title compound.  
15

7.4 Synthesis of N-methyl-N-(2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.4 using N-(2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide  
20 to give the title compound.

7.5 Synthesis of N-methyl-N-(2-(3,4-dimethoxyphenyl)-4-hydroxybutyl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(3,4-dimethoxyphenyl)-4-(t-butyldimethylsilyloxy)butyl)benzamide to give the title  
25 30 compound.

7.6 Synthesis of N-methyl-N-(2-(3,4-dimethoxyphenyl)-4-methanesulfonylbutyl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(3,4-dimethoxyphenyl)-4-hydroxybutyl)benzamide and methanesulfonyl chloride to give the title compound.  
35

7.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethoxyphenyl)butyl)benzamide

5 Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dimethoxyphenyl)-4-methanesulfonylbutyl)benzamide and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

10


EXAMPLE 8

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(benzo[1,3]dioxol-5-yl)butyl)benzamide

15

20

25



8.1 Synthesis of 2-(benzo[1,3]dioxol-5-yl)-4-(t-butyldimethylsilyloxy)butyronitrile

30 Prepare by the method of Example 1.1.1 using benzo[1,3]dioxol-5-ylacetonitrile and 1-(t-butyldimethylsilyloxy)-2-bromoethane to give of the title compound.

8.2 Synthesis of 2-(benzo[1,3]dioxol-5-yl)-4-(t-butyldimethylsilyloxy)butylamine

35 Prepare by the method of Example 1.2 using 2-(benzo[1,3]dioxol-5-yl)-4-(t-



butyldimethylsilyloxy)butyronitrile to give the title compound.

5    8.3 Synthesis of N-(2-(benzo[1,3]dioxol-5-yl)-4-(t-butyl-  
butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.3 using 2-(benzo[1,3]dioxol-5-yl)-4-(t-butyl-  
butyldimethylsilyloxy)butylamine and benzoyl chloride to  
10 give the title compound.

8.4 Synthesis of N-methyl-N-(2-(benzo[1,3]dioxol-5-yl)-4-(t-butyl-  
butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.4 using N-(2-(benzo[1,3]dioxol-5-yl)-4-(t-  
15 butyldimethylsilyloxy)butyl)benzamide to give the title compound.

20    8.5 Synthesis of N-methyl-N-(2-(benzo[1,3]dioxol-5-yl)-4-hydroxybutyl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(benzo[1,3]dioxol-5-yl)-4-(t-  
butyldimethylsilyloxy)butyl)benzamide to give the title compound.

25    8.6 Synthesis of N-methyl-N-(2-(benzo[1,3]dioxol-5-yl)-4-methanesulfonylbutyl)benzamide


Prepare by the method of Example 1.6 using N-methyl-N-(2-(benzo[1,3]dioxol-5-yl)-4-hydroxybutyl)benzamide and  
30 methanesulfonyl chloride to give the title compound.

8.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(benzo[1,3]dioxol-5-yl)butyl)benzamide

35    Prepare by the method of Example 1.7 using N-methyl-N-(2-(benzo[1,3]dioxol-5-yl)-4-methanesulfonylbutyl)benzamide and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

EXAMPLE 9

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-  
5 carbonyl)piperidin-1-yl)-2-(naphth-2-yl)butyl)benzamide



20 9.1 Synthesis of 2-(naphth-2-yl)-4-(t-  
butyldimethylsilyloxy)butyronitrile

Prepare by the method of Example 1.1.1 using naphth-2-ylacetonitrile and 1-(t-butyldimethylsilyloxy)-2-bromoethane to give of the title compound.

25 9.2 Synthesis of 2-(naphth-2-yl)-4-(t-  
butyldimethylsilyloxy)butylamine

Prepare by the method of Example 1.2 using 2-(naphth-2-yl)-4-(t-butyldimethylsilyloxy)butyronitrile to give the title compound.

30

9.3 Synthesis of N-(2-(naphth-2-yl)-4-(t-  
butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.3 using 2-(naphth-2-yl)-4-(t-butyldimethylsilyloxy)butylamine and benzoyl  
35 chloride to give the title compound.

9.4 Synthesis of N-methyl-N-(2-(naphth-2-yl)-4-(t-  
butyldimethylsilyloxy)butyl)benzamide

Prepare by the method of Example 1.4 using N-(2-(naphth-2-yl)-4-(t-butyldimethylsilyloxy)butyl)benzamide to give the title compound.

5

9.5 Synthesis of N-methyl-N-(2-(naphth-2-yl)-4-hydroxybutyl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(naphth-2-yl)-4-(t-butyldimethylsilyloxy)butyl)benzamide to give the title compound.

10

9.6 Synthesis of N-methyl-N-(2-(naphth-2-yl)-4-methanesulfonylbutyl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(naphth-2-yl)-4-hydroxybutyl)benzamide and methanesulfonyl chloride to give the title compound.

15

9.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(naphth-2-yl)butyl)benzamide

20

Prepare by the method of Example 1.7 using N-methyl-N-(2-(naphth-2-yl)-4-methanesulfonylbutyl)benzamide and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.


25

30

35

EXAMPLE 10

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-  
5 carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,5-  
bis(trifluoromethyl)benzamide



20 10.1 Synthesis of N-(2-(3,4-dichlorophenyl)-4-(t-  
butyldimethylsilyloxy)butyl)-3,5-  
bis(trifluoromethyl)benzamide

Prepare by the method of Example 1.3 using 2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butylamine and  
25 3,5-bis(trifluoromethyl)benzoyl chloride to give the title compound.

30 10.2 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-  
butyldimethylsilyloxy)butyl)-3,5-  
bis(trifluoromethyl)benzamide

Prepare by the method of Example 1.4 using N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,5-bis(trifluoromethyl)benzamide to give the title compound.

35 10.3 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-  
hydroxybutyl)-3,5-bis(trifluoromethyl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-

3,5-bis(trifluoromethyl)benzamide to give the title compound.

5 10.4 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-3,5-bis(trifluoromethyl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)-3,5-bis(trifluoromethyl)benzamide and methanesulfonyl chloride  
10 to give the title compound.

10.5 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,5-bis(trifluoromethyl)benzamide

15 Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-3,5-bis(trifluoromethyl)benzamide and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.


20

EXAMPLE 11

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-trifluoromethylphenyl)butyl)-3,4,5-trimethoxybenzamide

25

30



35

11.1 Synthesis of 2-(3-trifluoromethylphenyl)-4-(t-butyldimethylsilyloxy)butyronitrile

Prepare by the method of Example 1.1.1 using 3-trifluoromethylphenylacetonitrile and 1-(t-

butyldimethylsilyloxy)-2-bromoethane to give the title compound.

5 11.2 Synthesis of 2-(3-trifluoromethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butylamine

Prepare by the method of Example 1.2 using 2-(3-trifluoromethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyronitrile to give the title  
10 compound.

11.3 Synthesis of N-(2-(3-trifluoromethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.3 using 2-(3-  
15 trifluoromethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butylamine and 3,4,5-  
trimethoxybenzoyl chloride to give the title compound.

20 11.4 Synthesis of N-methyl-N-(2-(3-trifluoromethylphenyl)-  
4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.4 using N-(2-(3-trifluoromethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-  
3,4,5-trimethoxybenzamide to give the title compound.

25 11.5 Synthesis of N-methyl-N-(2-(3-trifluoromethylphenyl)-  
4-hydroxybutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(3-trifluoromethylphenyl)-4-(t-  
butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to  
30 give the title compound.

11.6 Synthesis of N-methyl-N-(2-(3-trifluoromethylphenyl)-  
4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(3-trifluoromethylphenyl)-4-hydroxybutyl)-3,4,5-  
35 trimethoxybenzamide to give the title compound.

11.7 Synthesis of N-methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-trifluoromethylphenyl)butyl)-3,4,5-trimethoxybenzamide

- 5 Prepare by the method of Example 1.7 using N-methyl-N-(2-(3-trifluoromethylphenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.

10


EXAMPLE 12

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(thien-2-yl)butyl)-3,4,5-trimethoxybenzamide

15

20

25



12.1 Synthesis of 2-(thien-2-yl)-4-(t-butyltrimethylsilyloxy)butyronitrile

- Prepare by the method of Example 1.1.1 using thien-2-ylacetonitrile and 1-(t-butyltrimethylsilyloxy)-2-bromoethane to give of the title compound.

30

12.2 Synthesis of 2-(thien-2-yl)-4-(t-butyltrimethylsilyloxy)butylamine

- Combine 2-(thien-2-yl)-4-(t-butyltrimethylsilyloxy)butyronitrile (3.24 mmol) and cobalt(II)chloride hexahydrate (1.54 g, 6.48 mmol) in methanol (50 mL). While maintaining the temperature at or below 20°C with an ice-bath, add portionwise sodium

35

borohydride (2.17 g, 57 mmol). After the addition is complete, allow the reaction mixture to stand at ambient temperature for 18 hours. Evaporate the reaction mixture *in vacuo* to obtain a residue. Partition the residue between dichloromethane and a saturated aqueous solution of ammonium chloride. Adjust the pH of the aqueous layer to about 8 using a 1M aqueous solution of hydrochloric acid. Separate the layers and extract the aqueous layer several times with dichloromethane, combine the organic layers, dry over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *in vacuo* to give the title compound.

15 12.3 Synthesis of N-(2-(thien-2-yl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.3 using 2-(thien-2-yl)-4-(t-butyldimethylsilyloxy)butylamine and 3,4,5-trimethoxybenzoyl chloride to give the title compound.

20 12.4 Synthesis of N-methyl-N-(2-(thien-2-yl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.4 using N-(2-(thien-2-yl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

25 12.5 Synthesis of N-methyl-N-(2-(thien-2-yl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide

30 Prepare by the method of Example 1.5 using N-methyl-N-(2-(thien-2-yl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

12.6 Synthesis of N-methyl-N-(2-(thien-2-yl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

35 Prepare by the method of Example 1.6 using N-methyl-N-(2-(thien-2-yl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide and methanesulfonyl chloride to give the title compound.



12.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(thien-2-yl)butyl)-3,4,5-trimethoxybenzamide

- 5        Prepare by the method of Example 1.7 using N-methyl-N-(2-(thien-2-yl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

10


EXAMPLE 13

N-Methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(pyrid-3-yl)butyl)-3,4,5-trimethoxybenzamide

15

20

25



13.1 Synthesis of 2-(pyrid-3-yl)-4-(t-butyldimethylsilyloxy)butyronitrile

- 30        Prepare by the method of Example 1.1.2 using pyrid-3-ylacetonitrile and 1-(t-butyldimethylsilyloxy)-2-bromoethane to give of the title compound.

13.2 Synthesis of 2-(pyrid-3-yl)-4-(t-butyldimethylsilyloxy)butylamine

- 35        Prepare by the method of Example 12.2 using 2-(pyrid-3-yl)-4-(t-butyldimethylsilyloxy)butyronitrile to give the title compound.

13.3 Synthesis of N-(2-(pyrid-3-yl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.3 using 2-(pyrid-3-yl)-4-(t-butyl-  
dimethylsilyloxy)butylamine and 3,4,5-trimethoxybenzoyl chloride to give the title compound.

13.4 Synthesis of N-methyl-N-(2-(pyrid-3-yl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.4 using N-(2-(pyrid-3-yl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

13.5 Synthesis of N-methyl-N-(2-(pyrid-3-yl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(pyrid-3-yl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

13.6 Synthesis of N-methyl-N-(2-(pyrid-3-yl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide


Prepare by the method of Example 1.6 using N-methyl-N-(2-(pyrid-3-yl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide and methanesulfonyl chloride. Isolate by extraction using a saturated solution of sodium bicarbonate to give the title compound.

13.7 Synthesis of N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(pyrid-3-yl)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-(pyrid-3-yl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

EXAMPLE 14

N-Methyl-N-(4-(4-(4-benzhydrylidene)piperidin-1-yl)-2-(3,4-  
5 dichlorophenyl)butyl)benzamide




15 14.1 Synthesis of N-methyl-N-(4-(4-(4-  
benzhydrylidene)piperidin-1-yl)-2-(3,4-  
dichlorophenyl)butyl)benzamide

20 Prepare by the method of Example 2.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)benzamide and 4-benzhydrylidene-piperidine to give the title compound.

EXAMPLE 15

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-  
25 yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide



35 15.1 Synthesis of N-(2-(3,4-dichlorophenyl)-4-(t-  
butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.3 using 2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butylamine and

3,4,5-trimethoxybenzoyl chloride to give the title compound.

5 15.2 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.4 using N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

10

15.3 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-  
15 3,4,5-trimethoxybenzamide to give the title compound.

15.4 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)-3,4,5-  
20 trimethoxybenzamide and methanesulfonyl chloride to give the title compound.


15.5 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title  
30 compound.

35

EXAMPLE 16

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide




16.1 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)benzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.

EXAMPLE 17

N-Methyl-N-(4-(4-(1-(2-(morpholin-4-yl)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide




17.1 Synthesis of N-methyl-N-(4-(4-(1-(2-(morpholin-4-yl)thyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide

- 5        Combine N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-3,4,5-trimethoxybenzamide (0.70 mmol) and 4-(2-chloroethyl)morpholine hydrochloride (0.84 mmol), and potassium carbonate (3.36 mmol) in acetone (10 mL), water  
10    (4 mL), and dichloromethane (5 mL). Heat to reflux. After 20 hours, cool to ambient temperature and concentrate the reaction mixture *in vacuo* and dilute with ethyl acetate. Extract with saturated aqueous ammonium chloride solution, water, saturated aqueous sodium bicarbonate solution, and  
15    saturated aqueous sodium chloride solution. Dry the organic layer over MgSO<sub>4</sub>, filter, and concentrate *in vacuo* to give the title compound.

EXAMPLE 18

- 20    N-Methyl-N-(4-(4-(1-(3-ethoxycarbonylpropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide




- 35    18.1 Synthesis of N-methyl-N-(4-(4-(1-(3-ethoxycarbonylpropyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide

Combine N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide (1.35 mmol), ethyl 4-bromobutyrate (5.4 mmol), and potassium carbonate (2.24 g, 16.2 mmol) in 13/1 acetone/water (25 mL). Heat to reflux. After 38 hours, cool to ambient temperature and dilute with ethyl acetate. Extract with saturated aqueous ammonium chloride solution and saturated aqueous sodium chloride solution. Dry the organic layer over  $\text{MgSO}_4$ , filter, and concentrate *in vacuo* to give the title compound.

#### EXAMPLE 19

N-Methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide




19.1 Synthesis of N-methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide

Combine N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide (1.69 mmol), methyl (4-bromomethyl)benzoate (1.55 g, 6.76 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (2.06 g, 13.52 mmol) in acetonitrile (20 mL). Heat to reflux. After 72 hours,

dilute the reaction mixture with ethyl acetate and extract three times with saturated aqueous ammonium chloride solution, saturated aqueous sodium bicarbonate solution, water, and saturated aqueous sodium chloride solution. Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and concentrate *in vacuo* to give the title compound.

EXAMPLE 20

10 N-Methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-  
dichlorophenyl)butyl)benzamide




20.1 Synthesis of N-methyl-N-(4-(4-(1-(4-carboxybenzyl)-1H-  
benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-  
dichlorophenyl)butyl)benzamide

Combine N-methyl-N-(4-(4-(1-(4-methoxycarbonylbenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide (0.92 mmol) and lithium hydroxide hydrate (0.12 g, 2.75 mmol) in 4/1 tetrahydrofuran/water (45 mL). After 72 hours, dilute the reaction mixture with water and evaporate *in vacuo* to remove most of the tetrahydrofuran. Acidify to pH 2 using 1 M hydrochloric acid solution. Extract with three times with ethyl acetate. Dry the combined organic layers over  $\text{Na}_2\text{SO}_4$ , filter, and concentrate *in vacuo* to give the title compound.



EXAMPLE 21

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-(3,4-  
5 dichlorophenyl)butyl)benzamide



21.1 Synthesis of N-methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-  
benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-  
20 dichlorophenyl)butyl)benzamide

Combine N-methyl-N-(4-(4-(1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-(3,4-  
dichlorophenyl)butyl)benzamide (1.36 mmol), 2-chloroethyl  
ethyl ether (0.59 g, 5.44 mmol), and 1,8-  
diazabicyclo[5.4.0]undec-7-ene (1.66 g, 10.9 mmol) in  
25 acetonitrile (16 mL). Heat to reflux. After 18 hours,  
cool to ambient temperature and dilute the reaction mixture  
with ethyl acetate. Extract twice with saturated aqueous  
solution of ammonium chloride, 5% aqueous solution of  
sodium bicarbonate, water, and saturated aqueous solution  
30 of sodium chloride. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>,  
filter, and concentrate *in vacuo* to give the title compound.

PREPARATION 8Synthesis of 4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine

Combine 1-(t-butoxycarbonyl)-4-(1H-benzimidazole-2-carbonyl)piperidine (1.16 mmol), furfuryl alcohol (0.10 mL, 1.16 mmol), and triphenylphosphine (0.33 g, 1.28 mmol) in tetrahydrofuran (5 mL). Add diethyl azodicarboxylate (0.20 mL, 1.28 mmol). After 18 hours, evaporate the reaction mixture *in vacuo* to give a residue. Partition the residue between ethyl acetate and water. Separate the organic layer and extract with water and saturated aqueous sodium chloride solution. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give the title compound. Chromatograph the residue on silica gel eluting with 5% acetone/dichloromethane to give 1-(t-butoxycarbonyl)-4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine.


Cool 1-(t-butoxycarbonyl)-4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine (1.0 mmol), and dichloromethane (5 mL). Slowly add a cold solution of trifluoroacetic acid (1 mmol) in dichloromethane (2 mL). After 15 minutes, partition the reaction mixture between dichloromethane and saturated aqueous sodium bicarbonate solution. Separate the organic layer and extract with brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give the title compound.

30

35

EXAMPLE 22

N-Methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide



15 22.1 Synthesis of N-methyl-N-(4-(4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide and 4-(1-(fur-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

20

PREPARATION 9

25 Synthesis of 4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidine

Combine furfuryl alcohol (1 mL, 11.6 mmol) and tetrahydrofuran (20 mL). Add portionwise sodium hydride (0.57 g, 60% in oil, 14 mmol). After gas evolution ceases, add ethyl bromoacetate (1.3 mL, 11.7 mmol). Heat to reflux. After 2.5 hours cool to ambient temperature. After 18 hours, partition the reaction mixture between ethyl acetate and water. Separate the aqueous layer and extract twice with ethyl acetate. Combine the organic layers and extract with saturated aqueous sodium chloride solution, dry over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 1% ethyl acetate/dichloromethane to give ethyl

30

35

fur-2-ylmethoxyacetate:  $R_f=0.62$  (silica gel, 5% ethyl acetate/dichloromethane).


Combine ethyl 2-fur-2-ylmethoxyacetate (1.2 g, 6.5 mmol) and tetrahydrofuran (10 mL). Cool in an ice-bath. Add dropwise a solution of lithium aluminum hydride (8.0 mL, 1.0 M in THF, 8.0 mmol). After 2 hours, add water (0.3 mL), add 15% sodium hydroxide solution (0.3 mL), and add water (0.9 mL). Stir vigorously. After 15 minutes, filter the reaction mixture and dry the filtrate over  $\text{Na}_2\text{SO}_4$ , filter, and concentrate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 2% ethyl acetate/dichloromethane to give fur-2-ylmethyl 2-hydroxyethyl ether:  $R_f=0.22$  (silica gel, 5% acetone/dichloromethane).

Combine 1-(t-butoxycarbonyl)-4-(1H-benzimidazole-2-carbonyl)piperidine (1.71 g, 5.2 mmol), fur-2-ylmethyl 2-hydroxyethyl ether (0.74 g, 5.2 mmol), and triphenylphosphine (1.67 g, 6.4 mmol) in tetrahydrofuran (20 mL). Add diethyl azodicarboxylate (1.0 mL, 6.35 mmol). After 21 hours, evaporate the reaction mixture *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 5% acetone/dichloromethane to give 1-(t-butoxycarbonyl)-4-(1-(2-fur-2-ylmethoxy-ethyl)-1H-benzimidazole-2-carbonyl)piperidine:  $R_f=0.30$  (silica gel, 5% acetone/dichloromethane).

Combine 1-(t-butoxycarbonyl)-4-(1-(2-fur-2-ylmethoxy-ethyl)-1H-benzimidazole-2-carbonyl)piperidine (1.0 mmol) and dioxane (10 mL). Cool in an ice bath. Slowly add a solution of hydrochloric acid in dioxane (0.25 mL, 4 M, 1.0 mmol). After 45 minutes, dilute the reaction mixture with dichloromethane and extract with saturated aqueous sodium bicarbonate solution. Separate the organic layer and extract with brine. Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and evaporate *in vacuo* to give the title compound.

EXAMPLE 23

N-Methyl-N-(4-(4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-  
benzimidazole-2-carbonyl)piperidin-1-yl)-2-  
5 phenylbutyl)benzamide



23.1 Synthesis of N-methyl-N-(4-(4-(1-(2-(fur-2-ylmethyl)-1H-  
benzimidazole-2-carbonyl)piperidin-1-yl)-2-  
20 phenylbutyl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide and 4-(1-(2-(fur-2-ylmethoxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

25

PREPARATION 10

Synthesis of 4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-  
carbonyl)piperidine

Combine allyl hydroxyethyl ether (1.02 g, 10 mmol), and  
30 diisopropylethylamine (4.0 mL, 23 mmol), and  
dichloromethane (20 mL). Cool in an ice-bath. Add  
dropwise, methanesulfonyl chloride (1.0 mL, 13 mmol).  
After 1.5 hours, extract the reaction mixture with 1 M  
aqueous hydrochloric acid solution, saturated aqueous  
35 sodium bicarbonate solution, and saturated aqueous sodium  
chloride solution. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>,  
filter, and evaporate *in vacuo* to obtain allyl

methanesulfonylethyl ether:  $R_f=0.80$  (silica gel, 20% ethyl acetate/dichloromethane).

Combine 1-(t-butoxycarbonyl)-4-(1H-benzimidazole-2-carbonyl)piperidine (1.87 g, 5.68 mmol), allyl methanesulfonylethyl ether (1.83 g, 10.1 mmol), and potassium carbonate (1.60 g, 11.5 mmol) in acetone (21 mL) and water (7 mL). Heat to reflux. After 18 hours, concentrate the reaction mixture *in vacuo* to remove most of the acetone. Partition the concentrated reaction mixture between ethyl acetate and water. Separate the aqueous layer and extract three times with ethyl acetate. Extract the combined organic layers with saturated aqueous sodium chloride solution. Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and evaporate *in vacuo* to obtain a residue. Chromatograph the residue on silica gel eluting with 15% ethyl acetate/dichloromethane to give 1-(t-butoxycarbonyl)-4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-carbonyl)piperidine:  $R_f=0.48$  (silica gel, 20% ethyl acetate/dichloromethane).


Combine 1-(t-butoxycarbonyl)-4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-carbonyl)piperidine (1.0 mmol) and dioxane (3 mL). Add a solution of hydrochloric acid in dioxane (4 mL, 4 M, 16 mmol). After 30 minutes, partition the residue between ethyl acetate and saturated aqueous sodium bicarbonate solution. Separate the organic layer and extract with saturated aqueous sodium chloride solution. Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and evaporate *in vacuo* to give the title compound.

30

35

EXAMPLE 24

5 N-Methyl-N-(4-(4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide



24.1 Synthesis of N-methyl-N-(4-(4-(1-(2-allyloxyethyl)-1H-  
benzimidazole-2-carbonyl)piperidin-1-yl)-2-  
20 phenylbutyl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide and 4-(1-(2-allyloxyethyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

25 PREPARATION 11

Synthesis of 4-(1-(2-(3,3-dimethylallyloxy)ethyl)-1H-  
benzimidazole-2-carbonyl)piperidine


Prepare by the method of Preparation 10 using 3-methyl-2-butene hydroxyethyl ether.

30

35

EXAMPLE 25

N-Methyl-N-(4-(4-(1-(2-(3,3-dimethylallyloxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide




25.1 Synthesis of N-methyl-N-(4-(4-(1-(2-(3,3-dimethylallyloxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide

20 Prepare by the method of Example 1.7 using N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide and 4-(1-(2-(3,3-dimethylallyloxy)ethyl)-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

EXAMPLE 26

25 N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide



26.1 Synthesis of 2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyronitrile



Prepar by the method of Examp1 1.1.1 using 3-chlorophenylacetonitrile and 1-(t-butyldimethylsilyloxy)-2-bromoethane to give the title compound.

5

26.2 Synthesis of 2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butylamine

Prepare by the method of Example 1.2 using 2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyronitrile to  
10 give the title compound.

26.3 Synthesis of N-(2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.3 using 2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butylamine and  
15 3,4,5-trimethoxybenzoyl chloride to give the title compound.

26.4 Synthesis of N-methyl-N-(2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

20 Prepare by the method of Example 1.4 using N-(2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

26.5 Synthesis of N-methyl-N-(2-(3-chlorophenyl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide

25 Prepare by the method of Example 1.5 using N-methyl-N-(2-(3-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

30

26.6 Synthesis of N-methyl-N-(2-(3-chlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(3-chlorophenyl)-4-hydroxybutyl)-3,4,5-  
35 trimethoxybenzamide to give the title compound.

26.7 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide

5        Prepare by the method of Example 1.7 using N-methyl-N-(2-(3-chlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.


10

EXAMPLE 27

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide

15

20



25


27.1 Synthesis of N-methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide

30        Prepare by the method of Example 21.1 using N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide and 2-chloroethyl ethyl ether to give the title compound.

35

EXAMPLE 28

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide



28.1 Synthesis of 2-(4-chlorophenyl)-4-(t-butyltrimethylsilyloxy)butyronitrile

Prepare by the method of Example 1.1.1 using 4-chlorophenylacetonitrile and 1-(t-butyltrimethylsilyloxy)-2-bromoethane to give the title compound.

28.2 Synthesis of 2-(4-chlorophenyl)-4-(t-butyltrimethylsilyloxy)butylamine

Prepare by the method of Example 1.2 using 2-(4-chlorophenyl)-4-(t-butyltrimethylsilyloxy)butyronitrile to give the title compound.

28.3 Synthesis of N-(2-(4-chlorophenyl)-4-(t-butyltrimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.3 using 2-(4-chlorophenyl)-4-(t-butyltrimethylsilyloxy)butylamine and 3,4,5-trimethoxybenzoyl chloride to give the title compound.

28.4 Synthesis of N-methyl-N-(2-(4-chlorophenyl)-4-(t-butyltrimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.4 using N-(2-(4-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide to give the title compound.

5

28.5 Synthesis of N-methyl-N-(2-(4-chlorophenyl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.5 using N-methyl-N-(2-(4-chlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-  
10 3,4,5-trimethoxybenzamide to give the title compound.

28.6 Synthesis of N-methyl-N-(2-(4-chlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.6 using N-methyl-N-  
15 (2-(4-chlorophenyl)-4-hydroxybutyl)-3,4,5-trimethoxybenzamide to give the title compound.

28.7 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide


20 Prepare by the method of Example 1.7 using N-methyl-N-(2-(4-chlorophenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title  
25 compound.

30

35

EXAMPLE 29

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-  
5 trimethoxybenzamide




29.1 Synthesis of N-methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-  
benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-  
chlorophenyl)butyl)-3,4,5-trimethoxybenzamide

20     Prepare by the method of Example 21.1 using N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-chlorophenyl)butyl)-3,4,5-trimethoxybenzamide and 2-chloroethyl ethyl ether to give the title compound.

25

EXAMPLE 30

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-  
yl)-2-(3,4-dimethylphenyl)butyl)-3,4,5-trimethoxybenzamide



30.1 Synthesis of 2-(3,4-dimethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyronitrile

Prepare by the method of Example 1.1.1 using 3,4-  
5 dimethylphenylacetonitrile and 1-(t-butyl-  
dimethylsilyloxy)-  
2-bromoethane to give the title compound.

30.2 Synthesis of 2-(3,4-dimethylphenyl)-4-(t-  
butyl-  
dimethylsilyloxy)butylamine

10 Prepare by the method of Example 1.2 using 2-(3,4-  
dimethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyronitrile to  
give the title compound.

30.3 Synthesis of N-(2-(3,4-dimethylphenyl)-4-(t-  
butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

15 Prepare by the method of Example 1.3 using 2-(3,4-  
dimethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butylamine and  
3,4,5-trimethoxybenzoyl chloride to give the title  
compound.

20

30.4 Synthesis of N-methyl-N-(2-(3,4-dimethylphenyl)-4-(t-  
butyl-  
dimethylsilyloxy)butyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.4 using N-(2-(3,4-  
dimethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-3,4,5-  
25 trimethoxybenzamide to give the title compound.

30.5 Synthesis of N-methyl-N-(2-(3,4-dimethylphenyl)-4-  
hydroxybutyl)-3,4,5-trimethoxybenzamide

Prepare by the method of Example 1.5 using N-methyl-N-  
30 (2-(3,4-dimethylphenyl)-4-(t-butyl-  
dimethylsilyloxy)butyl)-  
3,4,5-trimethoxybenzamide to give the title compound.

30.6 Synthesis of N-methyl-N-(2-(3,4-dimethylphenyl)-4-  
methanesulfonylbutyl)-3,4,5-trimethoxybenzamide

35 Prepare by the method of Example 1.6 using N-methyl-N-  
(2-(3,4-dimethylphenyl)-4-hydroxybutyl)-3,4,5-  
trimethoxybenzamide to give the title compound.

30.7 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dimethylphenyl)butyl)-3,4,5-trimethoxybenzamide

- 5        Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dimethylphenyl)-4-methanesulfonylbutyl)-3,4,5-trimethoxybenzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.


10

EXAMPLE 31

N-Methyl-N-(4-(4-(1-(imidazol-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide

15

20



25

31.1 Synthesis of N-methyl-N-(4-(4-(1-(1-benzylimidazol-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide

- 30        Prepare by the method of Example 21.1 using N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide and 1-benzyl-imidazol-2-ylmethylchloride hydrochloride to give the title compound.

35

31.2 Synthesis of N-methyl-N-(4-(4-(1-(1-benzylimidazol-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide

- Combine N-methyl-N-(4-(4-(1-(1-benzylimidazol-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-phenylbutyl)benzamide (5 mmol) and 10% palladium-on-carbon (1.5 g) in methanol (50 mL). Add anhydrous ammonium formate (25 mmol). Heat to reflux. After 18 hours,

filter, rins with dichloromethane, and evaporate the filtrate *in vacuo* to give th title compound.

5

PREPARATION 12Synthesis of 4-(1-(2-ethoxyethyl)-1H-benzimidazole)-4-hydroxypiperidine

Combine 1-(2-ethoxyethyl)-1H-benzimidazole (2.0 g, 10.51 mmol) and tetrahydrofuran (20 mL). Cool to -78°C  
10 using a dry-ice/acetone bath. Add dropwise a solution of lithium diisopropylamide (4.62 mL, 2.5 M in hexane, 11.56 mmol). After 1 hour, add dropwise a solution of 1-(t-butoxycarbonyl)piperidin-4-one (2.09 g, 10.51 mmol) in tetrahydrofuran (10 mL). Warm to ambient temperature over  
15 3 hours. Add water and separate the layers. Extract the aqueous layer three times with ethyl acetate. Dry the combined organic layers over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 1/1 ethyl acetate/hexane to give 1-  
20 (t-butoxycarbonyl)-4-(1-(2-ethoxyethyl)-1H-benzimidazole)-4-hydroxypiperidine: R<sub>f</sub>=0.25 (silica gel, 1/1 ethyl acetate/hexane).

Cool 1-(t-butoxycarbonyl)-4-(1-(2-ethoxyethyl)-1H-benzimidazole)-4-hydroxypiperidine (2.05 g) using an ice  
25 bath. Add dropwise trifluoroacetic acid (25 mL). After 1 hour, add diethyl ether (100 mL) and evaporate *in vacuo* to give a residue. Add dichloromethane and a 5% potassium carbonate solution. Stir vigorously. After 3 hours, separate the layers and extract the aqueous layer three  
30 times with dichloromethane. Combine the organic layers and dry over K<sub>2</sub>CO<sub>3</sub>, filter, and evaporate *in vacuo* to give the title compound: R<sub>f</sub>=0.3 (silica gel, 2% triethylamine/ethyl acetate).

35




EXAMPLE 32

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole)-4-hydroxypiperidin-1-yl)-2-phenylbutyl)benzamide

5

10

15



32.1 Synthesis of N-methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole)-4-hydroxypiperidin-1-yl)-2-phenylbutyl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-(2-phenyl-4-methanesulfonylbutyl)benzamide and 4-(1-(2-ethoxyethyl)-1H-benzimidazole)-4-hydroxypiperidine to give the title compound.

25

30

35

PREPARATION 135 Synthesis of 2-methoxy-5-(1H-tetrazol-1-yl)benzoyl chloride

Combine 2-hydroxy-5-nitrobenzoic acid (21.5 g, 117 mmol), potassium carbonate (162.3 g, 1.174 mol), and methyl iodide (136.8 g, 96.4 mmol) in acetone (500 mL). Heat to reflux. After 18 hours, cool the reaction mixture to ambient temperature and add methyl iodide (136.8 g, 96.4 mmol). Again, heat to reflux. After 56 hours, cool the reaction mixture to ambient temperature and filter, rinse with acetone, and evaporate the filtrate *in vacuo* to give a residue. Recrystallize the residue from ethanol to give a second residue. Combine the second residue and chloroform (about 100 mL), filter and evaporate the filtrate *in vacuo* to give methyl 2-methoxy-5-nitrobenzoate.  $R_f=0.38$  (silica gel, ethyl acetate/hexane 1/1).

Combine methyl 2-methoxy-5-nitrobenzoate (13.3 g, 63 mmol) and methanol. Add 5% palladium-on-carbon (0.66 g). Hydrogenate on a pressure apparatus at 50 psi. After 17 hours, filter through celite to remove the catalyst and evaporate the filtrate *in vacuo* to give a residue. Combine the residue and dichloromethane and extract with water. Dry the organic layer over  $\text{Na}_2\text{SO}_4$ , filter, and evaporate *in vacuo* to give methyl 2-methoxy-5-aminobenzoate.  $R_f=0.18$  (silica gel, ethyl acetate/methanol 1/1). Elemental Analysis calculated for  $\text{C}_9\text{H}_{11}\text{NO}_3$ : C, 59.66; H, 6.12; N, 7.73. Found: C, 59.44; H, 6.04; N, 7.62.

Combine methyl 2-methoxy-5-aminobenzoate (3.94 g, 21.7 mmol) and triethyl orthoformate (12.8 g, 86.7 mmol) in glacial acetic acid (20 mL). After 20 hours, concentrate the reaction mixture *in vacuo* to remove ethanol. Add glacial acetic acid (20 mL) and sodium azide (5.64 g, 86.7 mmol). Heat to 70°C. After 1 hour, add glacial acetic acid (10 mL) and continue to heat to 70°C. After an additional hour, cool the reaction mixture to ambient temperature, dilute with water (500 mL). Collect the solid by

filtration, rinse with water, and dry to give methyl 2-methoxy-5-(1H-tetrazol-1-yl)benzoate.

Combine methyl 2-methoxy-5-(1H-tetrazol-1-yl)benzoate  
5 (2.86 g, 12.2 mmol) and a 1 M aqueous solution of sodium hydroxide (13.43 mL, 13.43 mmol) in methanol/water (100 mL, 5:1 vol./vol.). Heat to reflux. After 4 hours, concentrate *in vacuo* to remove most of the methanol, add water (50 mL), and adjust the pH to about 4 using a 1 M  
10 aqueous hydrochloric acid solution. Evaporate *in vacuo* to give a solid, slurry the solid with water, filter, and dry to give 2-methoxy-5-(1H-tetrazol-1-yl)benzoic acid.

Alternately, combine methyl 2-methoxy-5-(1H-tetrazol-1-yl)benzoate (13.3 g, 56.8 mmol) and methanol (150 mL). Add  
15 1 M aqueous solution of sodium hydroxide (62.5 mL, 62.5 mmol). Heat to reflux. After 30 minutes, add methanol (50 mL) and water (50 mL) and continue the heat at reflux. After 1 hour, concentrate *in vacuo* to remove most of the solvent. Adjust the pH to about 1 to 2 using a 1 M aqueous  
20 hydrochloric acid solution to give a solid. Collect the solid by filtration, rinse with water, and dry to give 2-methoxy-5-(1H-tetrazol-1-yl)benzoic acid.


Combine 2-methoxy-5-(1H-tetrazol-1-yl)benzoic acid (1.2 g, 5.5 mmol) and dichloromethane (40 mL). Add dropwise  
25 oxalyl chloride (0.72 mL, 8.25 mmol) followed by dimethylformamide (3 drops). After 4 hours, evaporate *in vacuo* and dry to give the title compound.

30

35

EXAMPLE 33

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide



33.1 Synthesis of N-(2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

20        Combine 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butylamine (5.0 g, 16.8 mmol) and sodium bicarbonate (7.0 g, 83 mmol) in acetone (50 mL) and water (50 mL). Add 2-methoxy-5-(1H-tetrazol-1-yl)benzoyl chloride (3.3 g, 14.55 mmol). After 18 hours, dilute the reaction mixture with ethyl acetate, separate the layers, and extract the organic layer with a saturated aqueous solution of sodium bicarbonate, water, and then with brine. Dry the organic layer over  $\text{MgSO}_4$ , filter, and concentrate *in vacuo* to obtain a residue. Chromatograph the residue on

25

30        silica gel eluting sequentially with 50% ethyl acetate/hexane and then 75% ethyl acetate/hexane to give, after drying, the title compound:  $R_f=0.58$  (silica gel, ethyl acetate).

35        33.2 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

Combine N-(2-(4-fluorophenyl)-4-(t-butyl-  
butyldimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-  
yl)benzamide (3.57 g, 7.13 mmol) in tetrahydrofuran (20  
5 mL). Cool in a dry-ice/acetone bath. Add a solution of  
sec-butyllithium (7.2 mL, 1.3 M in cyclohexane, 9.5 mmol).  
After 30 minutes, add iodomethane (2.0 mL, 32.1 mmol).  
Warm to ambient temperature and then heat to reflux. After  
18 hours, cool, dilute the reaction mixture with ethyl  
10 acetate, and extract with a saturated aqueous solution of  
sodium bicarbonate and then brine. Dry the organic layer  
over Na<sub>2</sub>SO<sub>4</sub>, filter, and concentrate *in vacuo* to give a  
residue. Chromatograph the residue on silica gel eluting  
with 3/7 ethyl acetate/hexane to give, after drying, the  
15 title compound: R<sub>f</sub>=0.63 (silica gel, ethyl acetate).

33.3 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-  
hydroxybutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

Prepare by the method of Example 1.5 using N-methyl-N-  
20 (2-(4-fluorophenyl)-4-(t-butyl-  
butyldimethylsilyloxy)butyl)-2-  
methoxy-5-(1H-tetrazol-1-yl)benzamide to give the title  
compound: R<sub>f</sub>=0.18 (silica gel, ethyl acetate).

33.4 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-  
methanesulfonylbutyl)-2-methoxy-5-(1H-tetrazol-1-  
25 yl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-  
(2-(4-fluorophenyl)-4-hydroxybutyl)-2-methoxy-5-(1H-  
tetrazol-1-yl)benzamide to give the title compound.


30

33.5 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-2-  
methoxy-5-(1H-tetrazol-1-yl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-  
35 (2-(4-fluorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-  
(1H-tetrazol-1-yl)benzamide and 4-(1H-benzimidazole-2-  
carbonyl)piperidine hydriodic acid salt to give the title  
compound.

EXAMPLE 34

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide



34.1 Synthesis of N-(2-(3,4-dichlorophenyl)-4-(t-butyl dimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

20 Prepare by the method of Example 33.1 using 2-(3,4-dichlorophenyl)-4-(t-butyl dimethylsilyloxy)butylamine (5.0 g, 16.8 mmol) to give the title compound.

34.2 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-butyl dimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

25 Prepare by the method of Example 1.4 using N-(2-(3,4-dichlorophenyl)-4-(t-butyl dimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide to give the title compound.

34.3 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

35 Prepare by the method of Example 1.5 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-butyl dimethylsilyloxy)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide to give the title compound.

34.4 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

- 5        Prepare by the method of Example 1.6 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide to give the title compound.

10       34.5 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide

- 15       Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.

PREPARATION 14

Synthesis of 2,2,2-trifluoroethyl trifluoromethanesulfonate


- 20       Combine 2,2,2-trifluoroethanol (12.4 mL g, 170 mmol), pyridine (13.6 mL, 170 mmol), and dichloromethane (40 mL). Cool in an ice bath. Add trifluoromethanesulfonic anhydride (50 g, 196 mmol) over about 45 minutes. After 15 minutes, add water, separate the layers and extract the  
25       organic layer with water. Dry the organic layer over MgSO<sub>4</sub>, filter, and concentrate through a short path distillation apparatus to give the title compound: bp 89-91°C.

30

35

EXAMPLE 35

N-Methyl-N-(4-(4-(1-(2,2,2-trifluoroethyl)-1H-  
5 benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-  
fluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide



35.1 Synthesis of N-methyl-N-(4-(4-(1-(2,2,2-  
trifluoroethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-  
yl)-2-(4-fluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-  
20 yl)benzamide

Prepare by the method of Example 21.1 using 2,2,2-trifluoroethyl trifluoromethanesulfonate to give the title compound.

25 PREPARATION 15  
Synthesis of 4-(1-allyl-1H-benzimidazole-2-  
carbonyl)piperidine

Prepare by the method of Preparation 8 using allyl alcohol to give the title compound.


30

35



EXAMPLE 36

N-Methyl-N-(4-(4-(1-allyl-1H-benzimidazole-2-  
 5 carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-  
methoxy-5-(1H-tetrazol-1-yl)benzamide



36.1 Synthesis N-methyl-N-(4-(4-(1-allyl-1H-benzimidazole-  
2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-  
methoxy-5-(1H-tetrazol-1-yl)benzamide

20 Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide and 4-(1-allyl-1H-benzimidazole-2-carbonyl)piperidine to give the title compound.

25

PREPARATION 16

Synthesis of 2-methoxy-5-(4H-triazol-4-yl)benzoyl chloride

According to the method of J. Chem. Soc. (C), 1664 (1967), combine methyl 2-methoxy-5-aminobenzoate (2.0 g, 11 mmol), N,N-dimethylformamide azine (1.56 g, 11 mmol), p-toluenesulfonic acid (190 mg) in toluene (25 mL). Fit the reaction vessel with a gas inlet such that the head space of the vessel is swept with argon and scrub the effluent through dilute aqueous hydrochloric acid solution. Heat to reflux. After 20 hours, concentrate the reaction mixture *in vacuo* to give a residue. Partition the residue between dichloromethane and a saturated aqueous sodium bicarbonate solution. Extract the aqueous layer twice with

30

35

dichloromethane. Combine the organic layers, dry over  $\text{MgSO}_4$ , filter, and evaporate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting

- 5 sequentially with 70% ethyl acetate/dichloromethane and then 5% methanol/dichloromethane to give a residue. Recrystallize the residue from ethyl acetate/hexane to give methyl 2-methoxy-5-(4H-triazol-4-yl)benzoate: mp; 191-195.5°C.

- 10 Alternately, according to the method of J. Med. Chem., 21, 1100 (1978), combine methyl 2-methoxy-5-aminobenzoate (1.8 g, 10 mmol), diformyl hydrazine (0.97 g, 11 mmol), and phosphorous pentoxide (1.84 g, 13 mmol). Heat to 160°C. After 1.5 hours, cool the reaction mixture and add a
- 15 saturated aqueous solution of sodium bicarbonate. Extract three times with dichloromethane. Dry the combined organic layers over  $\text{MgSO}_4$ , filter, and evaporate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting sequentially with 40% ethyl acetate/dichloromethane and
- 20 then 5% methanol/dichloromethane to give methyl 2-methoxy-5-(4H-triazol-4-yl)benzoate: mp; 179-182°C.


Combine methyl 2-methoxy-5-(4H-triazol-4-yl)benzoate (56 mmol) and methanol (200 mL) and water (50 mL). Add 1 M aqueous solution of sodium hydroxide (62.5 mL, 62.5 mmol).

- 25 Heat to reflux. After 8 hour, concentrate *in vacuo* to remove most of the solvent. Adjust the pH to about 1 to 2 using a 1 M aqueous hydrochloric acid solution, extract with dichloromethane. Dry the organic layer over  $\text{MgSO}_4$ , filter, and evaporate *in vacuo* to give 2-methoxy-5-(4H-triazol-4-yl)benzoic acid.
- 30

- Combine 2-methoxy-5-(4H-triazol-4-yl)benzoic acid (5 mmol) and dichloromethane (40 mL). Add dropwise oxalyl chloride (0.72 mL, 8.25 mmol) followed by dimethylformamide (3 drops). After 4 hours, evaporate *in vacuo* and dry to give
- 35 the title compound.

EXAMPLE 37

N-Methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-  
5 carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-2-  
methoxy-5-(4H-triazol-4-yl)benzamide



37.1 Synthesis of N-(2-(4-fluorophenyl)-4-(t-  
20 butyldimethylsilyloxy)butyl)-2-methoxy-5-(4H-triazol-4-  
yl)benzamide

Prepare by the method of Example 33.1 using 2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butylamine and 2-methoxy-5-(4H-triazol-4-yl)benzoyl chloride to give the title compound.

25

37.2 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-(t-  
butyldimethylsilyloxy)butyl)-2-methoxy-5-(4H-triazol-4-  
yl)benzamide

Prepare by the method of Example 1.4 using N-(2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide to give the title compound.

30

37.3 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-  
hydroxybutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide

35 Prepare by the method of Example 1.5 using N-methyl-N-(2-(4-fluorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide to give the title compound.

37.4 Synthesis of N-methyl-N-(2-(4-fluorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-(4H-triazol-4-

5 yl)benzamide

Prepare by the method of Example 1.6 using N-methyl-N-(2-(4-fluorophenyl)-4-hydroxybutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide to give the title compound.

10 37.5 Synthesis of N-methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide

15 Prepare by the method of Example 1.7 using N-methyl-N-(2-(4-fluorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-(4H-triazol-4-yl)benzamide and 4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.

PREPARATION 18

20 Synthesis of 2-methoxy-5-trifluoromethoxybenzoyl chloride

Combine 2-methoxy-5-trifluoromethoxybenzene (1.0 g, 5.2 mmol) and trifluoroacetic acid (200 mL). Add slowly portionwise hexamethylenetetraamine (26 g, 185.7 mmol). Heat at 60°C. After 24 hours, cool to ambient temperature and pour the reaction mixture into a 2 M aqueous solution of sulfuric acid (500mL). Cool and extract ten times with diethyl ether. Dry the combined organic layers over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give a residue. Chromatograph the residue on silica gel eluting with 1/4 ethyl acetate/hexane to give 2-methoxy-5-trifluoromethoxybenzaldehyde.

35 According to the method of Heterocycles, 16, 2091 (1981), combine 2-methoxy-5-trifluoromethoxybenzaldehyde (0.58 g, 2.65 mmol) and 2-methylbut-2-ene (37 mL) in t-butanol (16 mL). Add dropwise a solution of sodium dihydrogen phosphate hydrate (0.92 g) and sodium chlorite (0.42 g, 4.7 mmol) in water (10 mL). After 4 hours, adjust the pH of the reaction mixture to about 8 to 9 using a 1 M

aqueous sodium hydroxide solution. Evaporate the reaction mixture *in vacuo* at about ambient temperature to remove most of the t-butanol. Add water (40 mL) and extract three  
5 times with hexane (10 mL). Adjust the pH of the aqueous layer to about 1 using a 1 M aqueous hydrochloric acid solution and extract five times with diethyl ether. Combine the organic layers, dry over Na<sub>2</sub>SO<sub>4</sub>, filter, and evaporate *in vacuo* to give a residue. Chromatograph the  
10 residue on silica gel eluting with 1/1 ethyl acetate/hexane containing 0.5% acetic acid to give 2-methoxy-5-trifluoromethoxybenzoic acid: R<sub>f</sub>=0.34 (silica gel, 1/1 ethyl acetate/hexane containing 0.5% acetic acid).

Combine 2-methoxy-5-trifluoromethoxybenzoic acid (0.6  
15 g, 2.53 mmol) and dichloromethane (10 mL). Cool in an ice bath. Add dropwise oxalyl chloride (0.64 mL, 5.0 mmol) followed by dimethylformamide (1 drop). Warm to ambient temperature. After 3 hours, evaporate *in vacuo* and dry to give the title compound.

20


25

30

35

EXAMPLE 38

N-Methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-  
5 trifluoromethoxybenzamide



38.1 Synthesis of N-(2-(3,4-dichlorophenyl)-4-(t-  
butyldimethylsilyloxy)butyl)-2-methoxy-5-  
trifluoromethoxybenzamide

20 Prepare by the method of Example 33.1 using 2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butylamine (5.0 g, 16.8 mmol) and 2-methoxy-5-trifluoromethoxybenzoyl chloride to give the title compound.

25 38.2 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-  
butyldimethylsilyloxy)butyl)-2-methoxy-5-  
trifluoromethoxybenzamide

30 Prepare by the method of Example 1.4 using N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-2-methoxy-5-trifluoromethoxybenzamide to give the title compound.

38.3 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-  
hydroxybutyl)-2-methoxy-5-trifluoromethoxybenzamide

35 Prepare by the method of Example 1.5 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-(t-butyldimethylsilyloxy)butyl)-2-methoxy-5-trifluoromethoxybenzamide to give the title compound.

38.4 Synthesis of N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-trifluoromethoxybenzamide


5        Prepare by the method of Example 1.6 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-hydroxybutyl)-2-methoxy-5-trifluoromethoxybenzamide to give the title compound.

38.5 Synthesis of N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-trifluoromethoxybenzamide

10        Prepare by the method of Example 1.7 using N-methyl-N-(2-(3,4-dichlorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-trifluoromethoxybenzamide and 4-(1H-benzimidazole-2-carbonyl)piperidine hydriodic acid salt to give the title compound.

EXAMPLE 39

N-Methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-trifluoromethoxybenzamide



39.1 Synthesis of N-methyl-N-(4-(4-(1-(2-ethoxyethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-2-methoxy-5-trifluoromethoxybenzamide

35        Prepare by the method of Example 21.1 using N-methyl-N-(4-(4-(1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-

dichlorophenyl)butyl)-2-methoxy-5-trifluoromethoxybenzamide  
and 2-chloroethyl ethyl ether to give the title compound.

5

PREPARATION 17

Synthesis of 4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-  
benzimidazole-2-carbonyl)piperidine hydriodic acid salt

According to the procedure of Tet. Let., 35, 5997-6000  
(1994), combine 1-hydroxy-2-tetrahydropyran-2-yloxyethane  
10 (J. Chem. Soc. Chem. Commun., 1766 (1990)) (5.0 mmol), 1,1-  
diethylazodicarboxylate (10 mmol), 2,2,2-trifluoroethanol  
(100 mmol), and tributylphosphine (10 mmol) in benzene (100  
mL). After 6 hours, concentrate *in vacuo* to give a residue.  
Chromatograph on silica gel to give 2-tetrahydropyran-2-  
15 yloxyethyl 2,2,2-trifluorethyl ether.

Combine 2-tetrahydropyran-2-yloxyethyl but-2-en-1-yl  
ether (2 mmol) and magnesium bromide (6 mmol) in diethyl  
ether (10 mL). After 24 hours, extract with water and then  
brine. Dry the organic layer over Na<sub>2</sub>SO<sub>4</sub>, filter, and  
20 concentrate *in vacuo* to give 2-hydroxyethyl 2,2,2-  
trifluorethyl ether.


Prepare by the method of Preparation 9 using 2-  
hydroxyethyl 2,2,2-trifluorethyl ether and 1-(t-  
butoxycarbonyl)-4-(1H-benzimidazole-2-carbonyl)piperidine  
25 (2.0 g, 6.1 mmol) to give 1-(t-butoxycarbonyl)-4-(1-(2-  
(2,2,2-trifluoroethoxy)ethyl)-1H-benzimidazole-2-  
carbonyl)piperidine.

Combine 1-(t-butoxycarbonyl)-4-(1-(2-(2,2,2-  
trifluoroethoxy)ethyl)-1H-benzimidazole-2-  
30 carbonyl)piperidine (5.0 mmol) and dichloromethane (150  
mL). Cool to 0°C using an ice bath. Add hydriodic acid  
(gas) until the solution is saturated and stir. After 30  
minutes, again add hydriodic acid (gas) until the solution  
is saturated. After 2 hours, evaporate *in vacuo* to give,  
35 after drying, the title compound.



EXAMPLE 40

N-Methyl-N-(4-(4-(1-(2-(2,2,2-trifluoroethoxy)ethyl)-1H-  
5 benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-  
fluorophenyl)butyl)-2-methoxy-5-(1H-tetrazol-1-yl)benzamide



40.1 Synthesis of N-methyl-N-(4-(4-(1-(2-(2,2,2-  
20 trifluoroethoxy)ethyl)-1H-benzimidazole-2-  
carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-2-  
methoxy-5-(1H-tetrazol-1-yl)benzamide

Prepare by the method of Example 1.7 using N-methyl-N-  
(2-(4-fluorophenyl)-4-methanesulfonylbutyl)-2-methoxy-5-  
25 (1H-tetrazol-1-yl)benzamide and 4-(1-(2-(2,2,2-  
trifluoroethoxy)ethyl)-1H-benzimidazole-2-  
carbonyl)piperidine hydriodic acid salt to give the title  
compound.

30

35

The tachykinins are a class of neuropeptides which share a common C-terminus sequence, Phe-Xaa-Gly-Leu-Met-NH<sub>2</sub>. The tachykinins are widely distributed in the peripheral and central nervous systems where they bind to at least three receptor types. Among the tachykinin receptors, the NK<sub>1</sub>, NK<sub>2</sub>, and NK<sub>3</sub> receptors are defined by the preferred binding affinity of substance P, neurokinin A (NKA), and neurokinin B (NKB), respectively.

10

The use of tachykinin antagonists is indicated as therapy for a variety of tachykinin-mediated diseases and conditions, including: hypersensitivity reactions; adverse immunological reactions; asthma; bronchitis; allergic rhinitis, including seasonal rhinitis and sinusitis; allergies; contact dermatitis; atopic dermatitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; and emesis.

15

It is understood that tachykinin-mediated diseases and conditions are those diseases and conditions in which the tachykinins are involved, either in whole or in part, in their clinical manifestation(s). Moreover, the tachykinins involvement is not necessarily causative of a particular tachykinin-mediated disease and condition. Tachykinin antagonists are useful in controlling or providing therapeutic relief of those tachykinin-mediated diseases and conditions.

20

The present invention provides new and useful tachykinin antagonists of formula (1) or stereoisomers or pharmaceutically acceptable salts thereof.

30

In a further embodiment, as tachykinin antagonists the present invention provides a method of treating tachykinin-mediated diseases and conditions, including: hypersensitivity reactions; adverse immunological reactions; asthma; bronchitis; allergic rhinitis, including

35

seasonal rhinitis and sinusitis; allergies; contact dermatitis; atopic dermatitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; and  
5 emesis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula (1).

Immediate hypersensitivity can occur when an IgE  
10 antibody response is directed against innocuous antigens, such as pollen. During such a response there is generally a subsequent release of pharmacological mediators, such as histamine, by IgE-sensitized mast cells resulting in an acute inflammatory reaction. The characteristics of the  
15 response are determined by the tissue in which the reaction occurs and gives rise to allergic diseases including: allergic rhinitis, including seasonal rhinitis and sinusitis; pulmonary diseases, such as asthma; allergic dermatitis such as urticaria, angioedema, eczema, atopic  
20 dermatitis, and contact dermatitis; gastrointestinal allergies, such as those caused by food or drugs; cramping; nausea; vomiting; diarrhea; and ophthalmic allergies.

Histamine, producing its effects via activation of the  
25 H<sub>1</sub> receptor, is an important mediator of the above responses involved in immediate hypersensitivity. In the acute phase of allergic rhinitis, histamine H<sub>1</sub> receptor antagonists have been shown to effectively inhibit the nasal itchiness, rhinorrhea, and sneezing associated with that condition.  
30 However, histamine H<sub>1</sub> receptor antagonists are less effective in relieving nasal congestion. The acute response to allergen in rhinitis is often followed by a chronic inflammatory response during which the inflamed mucosa becomes hypersensitive to both antigens and  
35 nonspecific irritants. Histamine H<sub>1</sub> receptor antagonists are also ineffective in attenuating the symptoms of the chronic phase of the response.

The present invention provides new and useful histamine antagonists of formula (1) or stereoisomers or pharmaceutically acceptable salts thereof.

5

In a further embodiment, as histamine antagonists the present invention provides a method of treating allergic diseases, including: allergic rhinitis, including seasonal rhinitis and sinusitis; pulmonary diseases, such as asthma; 10 allergic dermatitis, such as urticaria, angioedema, eczema, atopic dermatitis, and contact dermatitis; gastrointestinal allergies, such as those caused by food or drugs; cramping; nausea; vomiting; diarrhea; and ophthalmic allergies in a patient in need thereof comprising administering to said 15 patient a therapeutically effective amount of a compound of formula (1).

In addition to histamine, the tachykinins, particularly substance P, are also important contributors to the 20 allergic response and produce some symptoms distinct from those produced by a histamine response. This occurs because sensory nerves of trigeminal origin, located around blood vessels and within the nasal mucosal lining, upon stimulation by irritants or inflammatory mediators, such as 25 histamine, will release tachykinins.

Patients with allergic rhinitis have been shown to have higher nasal levels of substance P when their rhinitis symptoms are present. Mosimann et al., J. Allergy Clin. Immunol. 92, 95 (1993); Takeyama et al., J. Pharm. Pharmacol. 46, 41 (1994); and Wantanabe et al., Ann. Otol. Rhinol. and Laryngol., 102, 16 (1993). In humans, topical or intravenous administration of tachykinins induces nasal obstruction, recruitment of inflammatory cells, glandular 35 secretion, and microvascular leakage in allergic rhinitis. The nasal obstruction produced by substance P was found to be NK<sub>1</sub> receptor mediated. Braunstein et al., Am. Rev. Respir. Dis., 144, 630 (1991); Devillier et al., Eur.

Respir. J. 1, 356 (1988). Furthermore, sensory nerve-mediated effects, such as nasal irritability and hyperresponsiveness which occurs in late phase allergic reactions, also result from tachykinin release. Anggard, Acta Otolaryngol. 113, 394 (1993). Depletion of tachykinins from nasal sensory nerves after chronic capsaicin administration improved rhinitic symptoms in affected individuals. Lacroix et al., Clin. and Exper. Allergy, 21, 595 (1991).

Antagonism of the effects of histamine on the  $H_1$  receptor is useful in the treatment of allergic diseases, such as rhinitis. Likewise, antagonism of the effects of the tachykinins, particularly substance P on its preferred receptor, is useful in the treatment of symptoms which are concurrent with allergic diseases. Therefore, the potential benefits of an antagonist with affinity at both the  $H_1$  and  $NK_1$  receptors would be to reduce or prevent clinical manifestations of allergic diseases which are mediated through both receptors.

More particularly, the present invention provides new and useful compounds of formula (1) or stereoisomers or pharmaceutically acceptable salts thereof which are both tachykinin antagonists and histamine antagonists.

In a further embodiment, as both tachykinin antagonists and histamine antagonists the present invention provides a method of treating allergic diseases, including: allergic rhinitis, including seasonal rhinitis and sinusitis; and inflammatory bowel diseases, including Crohn's diseases and ulcerative colitis, in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula (1).

Various diseases and conditions described to be treated herein, are well known and appreciated by those skilled in

the art. It is also recognized that one skilled in the art may affect the associated diseases by treating a patient presently afflicted with the diseases or by  
5 prophylactically treating a patient afflicted with the diseases with a therapeutically effective amount of the compounds of formula (1).

As used herein, the term "patient" refers to a warm  
10 blooded animal such as a mammal which is afflicted with a particular allergic disease. It is understood that guinea pigs, dogs, cats, rats, mice, horses, cattle, sheep, and humans are examples of animals within the scope of the meaning of the term.

15 As used herein, the term "therapeutically effective amount" of a compound of formula (1) refers to an amount which is effective in controlling the diseases described herein. The term "controlling" is intended to refer to all  
20 processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases described herein, but does not necessarily indicate a total elimination of all disease symptoms, and is intended to include prophylactic treatment of the diseases.

25 A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances.  
30 In determining the therapeutically effective amount, the dose, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of involvement or the severity  
35 of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the

use of concomitant medication; and other relevant circumstances.

5       A therapeutically effective amount of a compound of formula (1) is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day. Preferred amounts are able to be determined by one skilled in the art.

10

          In effecting treatment of a patient afflicted with diseases described above, a compound of formula (1) can be administered in any form or mode which makes the compound bioavailable in an effective amount, including oral,  
15   inhalation, and parenteral routes. For example, compounds of formula (1) can be administered orally, by inhalation of an aerosol or dry powder, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like. Oral or inhalation  
20   administration is generally preferred for treatment of allergic diseases. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease or  
25   condition to be treated, the stage of the disease or condition, and other relevant circumstances. (Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990)).

30       The compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and  
35   chemical properties of the compound selected, the chosen route of administration, and standard pharmaceutical practice. The compounds of the present invention, while effective themselves, may be formulated and administered

in the form of their pharmaceutically acceptable salts, such as acid addition salts or base addition salts, for purposes of stability, convenience of crystallization, increased solubility, and the like.

In another embodiment, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (1) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

The pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art. The pharmaceutical composition may be adapted for oral, inhalation, parenteral, or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solution, suspensions, or the like.

The compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% of the compound of the present invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the compound present in compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention may be determined by someone skilled in the art.



The tablets, pills, capsules, troches and the like may also contain one or more of the following adjuvants:

5 binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and  
10 sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene  
15 glycol or a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in  
20 addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

25

For the purpose of parenteral therapeutic administration, the compounds of the present invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of a compound of  
30 the invention, but may be varied to be between 0.1 and about 50% of the weight thereof. The amount of the compound of formula (1) present in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations are able to be determined by  
35 one skilled in the art.

The compounds of the present invention may also be administered by inhalation, such as by aerosol or dry

powder. Delivery may be by a liquefied or compressed gas or by a suitable pump system which dispenses the compounds of the present invention or a formulation thereof.

5 Formulations for administration by inhalation of compounds of formula (1) may be delivered in single phase, bi-phasic, or tri-phasic systems. A variety of systems are available for the administration by aerosol of the compounds of formula (1). Dry powder formulations are  
10 prepared by either pelletizing or milling the compound of formula (1) to a suitable particle size or by admixing the pelletized or milled compound of formula (1) with a suitable carrier material, such as lactose and the like. Delivery by inhalation includes the necessary container,  
15 activators, valves, subcontainers, and the like. Preferred aerosol and dry powder formulations for administration by inhalation can be determined by one skilled in the art.

20 The compounds of the present invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee  
25 wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Topical formulations may contain a concentration of the formula (1) or its pharmaceutical salt from about 0.1 to about 10% w/v (weight per unit volume).

30

The solutions or suspensions may also include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other  
35 synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as

acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

#### EXAMPLE A

##### Antagonism of [<sup>3</sup>H]-pyrilamine binding to histamine H<sub>1</sub> receptors by putative antagonists

One skilled in the art can measure the H<sub>1</sub> receptor affinity of proposed histamine antagonists as evaluated in rat brains or Chinese hamster ovary cells transfected with the human histamine H<sub>1</sub> receptor gene (CHOpcDNA3H1R cells).

For the studies in rat brain, young male rats are sacrificed by decapitation and the brains are immediately removed. The cortices are dissected and used immediately or stored at -20°C. For the studies in Chinese hamster ovary cells, confluent cells are freshly scraped from culture flasks. The tissues or cells are homogenized with a Polytron (setting no. 6 for 15 seconds) in 20 mL of 50 mM potassium sodium phosphate (pH 7.4, at 4°C). The homogenate is centrifuged at 48,000 x g for 12 minutes at 4°C. The pellet is resuspended using a Polytron (setting no. 6 for 15 seconds) in incubation buffer (50 mM potassium sodium phosphate, pH 7.4, at ambient temperature, containing 0.1% bovine serum albumin) to a concentration of 40 mg/mL and is immediately added to tubes to start the assay. The protein content of the crude membrane suspension can be determined by the method of O. H. Lowery et al., J. Biol. Chem., **193** 265 (1951).

The binding assay is carried out in duplicate in 12 x 75 mm polypropylene tubes in 50 mM potassium sodium phosphate (pH 7.4, at ambient temperature) containing 0.1% bovine serum albumin. The radioligand, [<sup>3</sup>H]-pyrilamine, is diluted in incubation buffer to a concentration of 2 nM and added to each tube (50 µL). The test compound is diluted in incubation buffer (10<sup>-10</sup> M to 10<sup>-5</sup> M) and is

added to the appropriate tubes (50  $\mu$ L). The assay is started by the addition of 250  $\mu$ L of well mixed tissue suspension. The final incubation volume is 0.5 mL. The assay is carried out at ambient temperature for 30 minutes. The incubation is terminated by the addition of 3.5 mL of 0.9% sodium chloride solution (4°C) and filtration through GF/B filters that have been presoaked overnight in 0.1% polyethyleneimine, using a Brandel cell harvester. The filters are rapidly washed with two 3.5 mL portions of incubation buffer and transferred to scintillation vials. Ecolume (9 mL) is added to the vials. The vials are shaken and allowed to set for 4 hours before being counted by liquid scintillation spectrometry. Specific binding is determined as the difference between tubes containing no test compound and the tubes containing 10  $\mu$ M promethazine. Total membrane bound radioactivity is generally about 5% of that added to the tubes. Specific binding is generally 75% to 90% of total binding as determined by the method of M. D. DeBacker et al., Biochem. and Biophys. Res. Commun., 197(3) 1601 (1991).

The molar concentration of compound that causes 50% inhibition of ligand binding at the screening dose (10  $\mu$ M) is the IC<sub>50</sub> value, and is expressed as the cumulative mean ( $\pm$  S.E.M.) for n separate experiments.

#### EXAMPLE B

##### Antagonism of iodinated tachykinin binding to NK<sub>1</sub> receptors by putative antagonists

One skilled in the art can measure the NK<sub>1</sub> receptor affinity of proposed tachykinin antagonists as evaluated in guinea pig lungs (Keystone Biologicals, Cleveland, OH). Tissues are homogenized with a Polytron in 15 volumes of 50 mM Tris-HCl buffer (pH 7.4, 4°C) and centrifuged. The pellet is resuspended in Tris-HCl buffer and centrifuged; the pellet is washed twice by resuspension. The final pellet is resuspended at a concentration of 40 mg/ml in

incubation buffer and remains at room temperature for at least 15 min prior to use.

Receptor binding is initiated by addition of 250  $\mu$ l  
5 membrane preparation in duplicate to 0.1 nM of  $^{125}$ I-Bolton  
Hunter Lys-3 labeled substance P in a final volume of 500  
 $\mu$ l of buffer containing 50 mM Tris-HCl (pH 7.4 at room  
temperature), 0.1% bovine serum albumin, 2 mM manganese  
chloride, 40  $\mu$ g/ml bacitracin, 4  $\mu$ g/ml leupeptin and  
10 chymostatin, 1  $\mu$ M thiorphan and various doses of the  
putative tachykinin antagonists. Incubations are  
performed at room temperature for 90 min; binding is  
terminated by addition of 50 mM Tris-HCl buffer (pH 7.4,  
4°C) and filtration under vacuum through GF/B filters  
15 presoaked with 0.1% polyethyleneimine. Filter bound  
radioactivity is quantitated in a gamma counter.  
Nonspecific binding is defined as binding in the presence  
of 1  $\mu$ M substance P.

Specific binding is calculated by subtracting  
20 nonspecific binding from total binding. Competition of  
iodinated substance P binding by test compounds or  
standards is expressed as a percentage of this maximum  
competition. IC<sub>50</sub> values (concentration required to  
inhibit 50% of receptor binding) are generated for each of  
25 the test compounds by nonlinear regression using an  
iterative curve fitting program (GraphPAD Inplot, San  
Diego, CA).

#### EXAMPLE C

##### 30 Histamine (H<sub>1</sub>) antagonism in guinea pig ileum

One skilled in the art can determine that the compounds  
of the present invention are H<sub>1</sub> receptor antagonists *in vitro*  
by evaluating the compound's ability to inhibit histamine  
mediated smooth muscle contraction. Male Hartley guinea  
35 pigs, weighing 200-450 grams, are sacrificed by CO<sub>2</sub>  
asphyxiation. A piece of ileum, about 20 cm in length, is  
removed and cut into 2 cm pieces. Each ileum piece is  
placed in an organ bath at 37°C containing Tyrode's

solution and is constantly aerated with 95% O<sub>2</sub>/5% CO<sub>2</sub>. Tyrode's solution has the composition: sodium chloride 136.9 mM, potassium chloride 2.68 mM, calcium chloride 1.8 mM, sodium dihydrogen phosphate 0.42 mM, sodium bicarbonate 11.9 mM, and dextrose 5.55 mM. Contractions are measured with an isometric transducer (Grass FT03C), and are recorded on a polygraph recorder and/or a computer. The ileum strips are loaded with 1.0 grams of tension and allowed to equilibrate for a minimum of 30 minutes before starting the experiments. Tissues are preincubated with vehicle or varying concentrations of test compound followed by histamine challenge.

A competitive H<sub>1</sub> receptor antagonist produces a parallel shift of the histamine dose-response curve to the right without a depression of the maximal response.

The potency of the antagonism is determined by the magnitude of the shift and is expressed as a pA<sub>2</sub> value which is the negative logarithm of the molar concentration of antagonist which produces a two-fold shift of the dose response curve to the right. The pA<sub>2</sub> value is calculated by using Schild analysis. O. Arunlakshana and H. O. Schild, Br. J. Pharmacol Chemother. 14, 48-58 (1958). When the slope of the lines obtained by a Schild analysis are not significantly different from one (1) the compound is acting as a competitive antagonist.

#### EXAMPLE D

##### Antagonism of tachykinin-induced phosphatidylinositol (PI) turnover *in vitro* by putative antagonists

One skilled in the art can determine NK<sub>1</sub> receptor antagonism by measuring the substance P-induced phosphatidylinositol (PI, inositol phosphate) accumulation in UCL1 cells in the presence and absence of NK<sub>1</sub> receptor antagonists. Cells are seeded onto 24-well plates at 125,000 cells/well, two or three days prior to the assay. Cells are loaded with 0.5 mL of 0.2 μM myo-[2-<sup>3</sup>H(N)] inositol (American Radiolabeled Chemicals Inc., specific

activity; 20  $\mu$ Ci/mmol) 20-24 hours prior to the assay. Cultured cells are maintained at 37°C in 5% CO<sub>2</sub> environment.

- 5 On the day of the assay, media is aspirated and the cells incubated in RPMI-1640 media containing 40  $\mu$ g/ml bacitracin, 4  $\mu$ g/ml each of leupeptin and chymostatin, 0.1% bovine serum albumin, 10  $\mu$ M thiorphan, and 10 mM lithium chloride. After 15 minutes, the test compound is
- 10 added to the cells in a volume of 0.1 mL. After another 15 min, substance P is added to UC11 cells at various concentrations to start the reaction followed by incubation for 60 min at 37°C in 5% CO<sub>2</sub> environment in a final volume of 1 mL. To terminate the reaction, the
- 15 media is aspirated and methanol (0.1 mL) is added to each well. Two aliquots of methanol (0.5 mL) are added to the wells to harvest the cells into chloroform resistant tubes. Chloroform (1 mL) is added to each tube followed by doubly distilled water (0.5 mL). Samples are vortexed
- 20 for 15 seconds and centrifuged at 1700 x g for 10 minutes. An aliquot (0.9 mL) of the aqueous (top) phase is removed and added to doubly distilled water (2 mL). The mixture is vortexed and loaded onto a 50% Bio-Rad AG 1-X8 (formate form, 100-200 mesh) exchange column (Bio-Rad Laboratories, Hercules, CA). The columns are washed, in order, with: 1)
- 25 10 ml doubly distilled water, 2) 5 mL of 5 mM disodium tetraborate/60 mM sodium formate, and 3) 2 mL of 1 M ammonium formate/0.1 M formic acid. The third elution is collected and counted in 9 mL scintillation fluid. A 50
- 30  $\mu$ l aliquot of the organic (bottom) phase is removed, dried in a scintillation vial and counted in 7 mL scintillation fluid.

The ratio of DPM in the aqueous phase aliquot (total inositol phosphates) to the DPM in the 50  $\mu$ l organic phase

35 aliquot (total [<sup>3</sup>H]inositol incorporated) is calculated for each sample. Data are expressed as a percent of agonist-induced accumulation of [<sup>3</sup>H]-inositol phosphates over basal levels. The ratios in the presence of test compound

and/or standards are compared to the ratios for control samples (i.e. no stimulating agonist).

Dose-response graphs are constructed and the ability of the test compounds to inhibit tachykinin-induced phosphatidylinositol turnover determined with the aid of a computer program. Data is expressed as percent stimulation of total inositol phosphate accumulation over basal levels and normalized to the maximum response produced by substance P. Schild analysis is performed using dose response curves to obtain a value indicative of the strength of a competitive antagonist and is expressed as the  $pA_2$ , which is the negative logarithm of the molar concentration of antagonist which reduces the effect of a dose of agonist to one-half of that expected at the dose of agonist. The slope of the lines obtained by a Schild analysis are not significantly different from one (1) the compound is acting as a competitive antagonist.

20

#### EXAMPLE E

##### Evaluation of $H_1$ (or $NK_1$ ) antagonism *in vivo*

One skilled in the art can determine that the compounds of the present invention mediate the immediate hypersensitivity response *in vivo* by evaluating the ability of the compounds to inhibit the formation of histamine (or substance P) induced wheals in guinea pigs. Animals are anesthetized with pentobarbitol (i.p.). Dorsal skin is shaved and intradermal injections of histamine (or substance P) are given in the shaved area at appropriate times after the administration of the test compounds. Doses, routes, and times of administration may vary according to experimental design. The design of such experiments is well known and appreciated in the art. Immediately after the intradermal challenges, the animal is given an intravenous injection of 1% Evan's blue dye to make the wheals visible. At an appropriate time after the challenge the animals are sacrificed by  $CO_2$  inhalation.



The skin is removed and the diameter of each wheal is measured in two perpendicular directions.

The wheal response is used as the index of the edema response. The percent of inhibition of the wheal response is calculated by comparing the drug-treated group to a vehicle-treated group. Linear regression of the dose-response inhibition curve is used to determine an ED<sub>50</sub> value, expressed in mg/kg, which is the dose of compound which inhibits histamine-induced skin wheal by 50%.

#### EXAMPLE F

##### Evaluation of NK<sub>1</sub> antagonism *in vivo*

One skilled in the art can also determine that the compounds of the present invention are NK<sub>1</sub> receptor antagonists *in vivo* by evaluating the compound's ability to inhibit substance P-induced plasma protein extravasation in guinea pig trachea. Substance P-induced protein leakage through postcapillary venules is assessed by measuring Evans Blue dye accumulation in guinea pig trachea.

When putative antagonists are administered intravenously, animals are anesthetized with pentobarbital then injected with Evans Blue dye (20 mg/kg, i.v., prepared in 0.9% sodium chloride solution). One minute after dye administration, the antagonist is administered (i.v.) followed by substance P (0.3 nmole/kg, i.v.) and, after 5 min, excess dye removed from the circulation by transcardiac perfusion with 50 ml 0.9% sodium chloride solution. The trachea and primary bronchi are removed, blotted dry and weighed.

When the putative antagonist is administered orally, animals are anesthetized with pentobarbital one hour after dosing and injected with Evans Blue dye (20 mg/kg, i.v., prepared in 0.9% sodium chloride solution). One minute after dye administration, administer substance P (0.3 nmole/kg, i.v.) and, after 5 min, excess dye removed from the circulation by transcardiac perfusion with 50 ml 0.9%

sodium chloride solution. The trachea and primary bronchi are removed, blotted dry and weighed.

Dye quantitation is performed spectrophotometrically  
5 (620 nm) after extracting tissues in formamide for 24 hr  
at 50°C. Values are subtracted from background (dye only,  
no agonist). ED<sub>50</sub> (dose of compound which inhibits  
substance P-induced plasma protein extravasation by 50%)  
is calculated from linear regression analysis.

10

15

20

25


30

35

5

WHAT IS CLAIMED IS:


10 1. A compound of the formula



wherein

20  $R'$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy;


$R''$  is hydrogen or a radical chosen from the group  
25 consisting of



wherein

$R_{20}$  is selected from the group consisting of  
35 hydrogen,  $C_1$ - $C_4$  alkyl, and  $-CF_3$ ;

Ar<sub>1</sub> is a radical chosen from the group consisting of



15 wherein

R<sub>1</sub> is from 1 to 3 substituents each independently  
chosen from the group consisting of hydrogen, halogen,  
hydroxy, -CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

20

R<sub>2</sub> is from 1 to 2 substituents each independently  
chosen from the group consisting of hydrogen, halogen,  
C<sub>1</sub>-C<sub>6</sub> alkyl, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

25 X<sub>1</sub> and X<sub>2</sub> are as defined in one of parts A), B), or C):

30



35

A)  $X_1$  is hydrogen;


$X_2$  is a radical chosen from the group consisting of

5


10



15




20



25

and



wherein

30

$p$  is 1 or 2;


35

$R_3$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $-CF_3$ ,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy;

$R_4$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $-CF_3$ ,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy,

$R_5$  is hydrogen or hydroxy;

$Ar_2$  is a radical chosen from the group consisting of



$R_6$  is from 1 to 3 substituents each independently chosen from the group consisting of hydrogen, halogen,  $-CF_3$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, and  $-CO_2R_9$  wherein  $R_9$  is chosen from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl;

$R_7$  is from 1 to 2 substituents each independently chosen from the group consisting of hydrogen, halogen,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkoxy;

$R_8$  is chosen from the group consisting of hydrogen,  $-CH_3$ , and  $-CH_2OH$ ;

$R_{10}$  is chosen from the group consisting of hydrogen,  $C_1$ - $C_4$  alkyl, and benzyl;

$Z$  is chosen from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl,  $-(CH_2)_w-O-(CH_2)_t-Y$ ,  $-(CH_2)_fA$ ,  $-(CH_2)_uCO_2R_{11}$ ,

5  $-(CH_2)_u C(O)NR_{12}R_{13}$ ,  $-(CH_2)_g C(O)(CH_2)_h CH_3$ ,  $-(CH_2)_w -O-Ar_3$ ,  
 $-CH_2CH_2OCF_3$ ,  $-CH_2CF_3$ ,  $-CH_2CH_2CH_2CF_3$ ,  $-(CH_2)_2CH=CH_2$ ,  
 $-CH_2CH=CH_2$ ,  $-CH_2CH=CHCH_3$ ,  $-CH_2CH=CHCH_2CH_3$ ,  
 $-CH_2CH=C(CH_3)_2$ , and  $-CH_2OCH_2CH_2Si(CH_3)_3$

wherein

10 w is an integer from 2 to 5;

t is an integer from 1 to 3;

f is 2 or 3;

15 u is an integer from 1 to 4;

g is an integer from 1 to 3;

h is an integer from 0 to 3;

20 w is an integer from 2 to 4;

Y is chosen from the group consisting of hydrogen,  
25  $-CF_3$ ,  $-CH=CH_2$ ,  $-CH=C(CH_3)_2$ , and  $-CO_2R_{14}$  wherein  $R_{14}$   
is chosen from the group consisting of hydrogen and  
 $C_1-C_4$  alkyl;

A is chosen from the group consisting of  $-NR_{15}R_{16}$ ,  
acetylamino, and morpholino wherein  $R_{15}$  is chosen  
30 from the group consisting of hydrogen and  $C_1-C_4$   
alkyl and  $R_{16}$  is  $C_1-C_4$  alkyl;


$R_{11}$  is chosen from the group consisting of hydrogen  
and  $C_1-C_4$  alkyl;

35  $R_{12}$  is chosen from the group consisting of  
hydrogen,  $C_1-C_4$  alkyl, and benzyl;

-150-

$R_{13}$  is chosen from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl;

5  $Ar_3$  is a radical chosen from the group consisting of



wherein


$v$  is an integer from 1 to 3;

15

$R_{17}$  is chosen from the group consisting of hydrogen and  $-CO_2R_{18}$  wherein  $R_{18}$  is chosen from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl;

20 B)  $X_1$  is hydroxy;

$X_2$  is a radical chosen from the group consisting of




30

wherein  $p$ ,  $R_3$ ,  $Z$ , and  $Ar_2$  are as previously defined;

35



C)  $X_2$  is a radical of the formula;




wherein  $R_3$  and  $R_4$  are as previously defined; and

$X_1$  and  $Z_1$  taken together form a second bond between the carbon atoms bearing  $X_1$  and  $Z_1$ ;

15 and stereoisomers and pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 wherein  $X_1$  is hydrogen.

20 3. A compound of Claim 2 wherein  $X_2$  is a radical of the formula



wherein  $R_3$ ,  $Ar_2$ , and  $p$  are as defined in Claim 1.

4. A compound of Claim 3 wherein  $R_3$  is hydrogen,  $p$  is 1, and  $Ar_2$  is 4-fluorophenyl.


35 5. A compound of Claim 3 wherein  $R_3$  is hydrogen,  $p$  is 1, and  $Ar_2$  is pyrid-2-yl.

6. A compound of Claim 3 wherein  $R_3$  is hydrogen,  $p$  is 1, and  $Ar_2$  is fur-2-yl.

7. A compound of Claim 3 wherein  $R_3$  is hydrogen,  $p$  is 1, and  $Ar_2$  is fur-3-yl.

8. A compound of Claim 2 wherein  $X_2$  is a radical of the formula

10



15

wherein  $R_3$  and  $Z$  are as defined in Claim 1.

9. A compound of Claim 8 wherein  $Z$  is  $-(CH_2)_w-O-(CH_2)_t-Y$  wherein  $w$ ,  $t$ , and  $Y$  are as defined in Claim 1.

20

10. A compound of Claim 9 wherein  $w$  is 2.


11. A compound of Claim 10 wherein  $Z$  is 2-ethoxyethyl.

25

12. A compound of Claim 1 wherein  $X_1$  is hydroxy.

13. A compound of Claim 12 wherein  $X_2$  is a radical of the formula

30



35

wherein  $R_3$ ,  $Ar_2$ , and  $p$  are as defined in Claim 1.

14. A compound of Claim 13 wherein  $R_3$  is hydrogen,  $p$  is 1, and  $Ar_2$  is 4-fluorophenyl.
- 5 15. A compound of Claim 1 wherein the compound is (+)- or (-)-N-methyl-N-(4-(4-(1-(pyrid-2-ylmethyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(4-fluorophenyl)butyl)-3,4,5-trimethoxybenzamide or a mixture thereof.
- 10 16. A compound of Claim 1 wherein the compound is (+)- or (-)-N-methyl-N-(4-(4-(1-(4-fluorobenzyl)-1H-benzimidazole-2-carbonyl)piperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)benzamide or a mixture thereof.
- 15 17. A pharmaceutical composition comprising a compound of Claim 1.
18. A pharmaceutical composition comprising a compound of
- 20 Claim 1 in admixture or otherwise in association with one or more inert carriers.
19. A method for treating allergic rhinitis in a patient in need thereof comprising administering to said patient a
- 25 therapeutically effective amount of a compound of Claim 1.
20. A method for treating asthma in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of Claim 1.
- 30 21. A method for treating emesis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of Claim 1.
- 35 22. A method for treating inflammatory bowel disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of Claim 1.

# INTERNATIONAL SEARCH REPORT

Int. Application No.  
PCT/US 97/02239

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/14 C07D401/06 C07D401/04 C07D405/14 C07D417/06  
C07D211/22 C07D409/14 C07D211/70 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 630 887 A (ZENECA LTD., UK) 28 December 1994 see claim 1	1,2,13, 17-22
X	EP 0 625 509 A (ZENECA LTD., UK) 23 November 1994 see claim 1	1-22
A	EP 0 515 240 A (ELF SANOFI, FR.) 25 November 1992 see the whole document	1-22
A	EP 0 474 561 A (SANOFI S. A., FR.) 11 March 1992 see the whole document	1-22

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

2 June 1997

Date of mailing of the international search report

16.06.1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Kissler, B

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/02239

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0630887 A	28-12-94	AU 673063 B	24-10-96
		AU 6320394 A	15-12-94
		CA 2124048 A	25-11-94
		CN 1098094 A	01-02-95
		FI 942381 A	25-11-94
		HU 70445 A	30-10-95
		JP 6340625 A	13-12-94
		NO 941906 A	25-11-94
		NZ 260566 A	26-07-96
EP 0625509 A	23-11-94	CA 2123636 A	18-11-94
		JP 6340624 A	13-12-94
		US 5521199 A	28-05-96
EP 0515240 A	25-11-92	FR 2676054 A	06-11-92
		AU 657321 B	09-03-95
		AU 1591892 A	05-11-92
		CA 2067924 A	04-11-92
		CS 9201328 A	18-11-92
		IL 101762 A	16-10-96
		JP 5140103 A	08-06-93
		NO 178572 B	15-01-96
		NZ 242584 A	27-04-95
		US 5606065 A	25-02-97
		US 5411971 A	02-05-95
EP 0474561 A	11-03-92	FR 2666335 A	06-03-92
		FR 2678267 A	31-12-92
		AU 657272 B	09-03-95
		AU 8354291 A	12-03-92
		CA 2050639 A	06-03-92
		CS 9102724 A	18-03-92
		FI 98457 B	14-03-97
		HU 9500521 A	30-10-95
		IL 99320 A	31-07-95
		JP 4261155 A	17-09-92
		LT 585 A,B	27-12-94
		LV 10606 B	20-04-96
		NO 177226 B	02-05-95
		NZ 239661 A	27-06-94

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/02239

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0474561 A		PL 167994 B	30-12-95
		RU 2070196 C	10-12-96
		US 5350852 A	27-09-94
		US 5236921 A	17-08-93
-----			